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Dimethylarginine dimethylaminohydrolase (DDAH) catalyzes the hydrolysis of
Nw–methyl–L–arginine (NMMA) and Nw,Nw–methyl–L–arginine (ADMA) to L-citrulline
and methylamine or dimethylamine, respectively.  ADMA and NMMA are endogenous
inhibitors of nitric oxide synthase (NOS) in mammals.  DDAH therefore partially
regulates NOS activity, making it an attractive therapeutic target in disease states
involving overproduction of nitric oxide.  Understanding the mechanism of DDAH is
important to inhibitor design and elucidating its physiological function.
DDAH is a member of the amidinotransferase superfamily, and has conserved
active–site residues including cysteine, histidine, and glutamate/aspartate that are integral
to catalysis.  In DDAH from Pseudomonas aeruginosa, the active–site Cys249 is
activated as a nucleophile upon binding substrate, and forms a covalent intermediate
concomitant with loss of the alkylamine leaving group.  The active–site His162 has a
vii
dual role, first as a general acid in protonating the alkylamine leaving group and second
as a general base in generating a hydroxide for attack on the covalent intermediate.  The
active–site Glu114 is essential for properly orienting and ionizing His162.  The use of a
substrate analog, S–methyl-L-thiocitrulline (SMTC), enabled development of a new
method of continuously monitoring DDAH activity, allowing facile screening of
inhibitors.  Using this method, a haloacetamidine was identified as an active–site directed
inactivator motif for DDAH, and other members of the amidinotransferase superfamily.
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Chapter 1 Introduction
NITRIC OXIDE AN IMPORTANT BIOMOLECULE
Nitric oxide (NO) is an important molecule for normal physiological function in
regulating blood pressure, immune cell function and neuronal signaling.  NO is produced
by the enzyme nitric oxide synthase (NOS), which catalyzes nitric oxide production
through a five electron oxidation of arginine, resulting in NO and citrulline (1).
Mammals have three NOS isozymes, neuronal NOS (nNOS) involved in neuronal
signaling via synaptic potentiation, endothelial NOS (eNOS), distributed in vascular
endothelium and important for smooth muscle relaxation and inducible NOS (iNOS)
which is involved in macrophage mediated immune response.  Although production of
NO is important to normal physiology, overproduction of NO is involved in a number of
disease states such as septic shock, rheumatoid arthritis, cerebral ischemic damage during
stroke, Parkinson’s, Huntington’s and various other diseases (2).  Regulation of NOS is
an area of intense research.
NOS REGULATION BY ADMA AND NMMA
Although eNOS and nNOS are primarily regulated in a Ca2+/calmodulin
dependent manner, and iNOS is transcriptionally regulated, asymmetric
Nw,Nw–dimethyl–L–arginine (ADMA) and Nw–methyl–L-arginine (NMMA) (Figure 1.1)
have recently been found to act as endogenous competitive inhibitors of NOS in
mammalian systems (3).  ADMA and NMMA are thought to be derived from proteins
that are post–translationally methylated on arginine residues by the protein arginine
methyl transferases (PRMTs), using S–adenosylmethionine as a cofactor for methyl
2
transfer. These proteins are subsequently degraded, releasing free ADMA and NMMA.
Symmetric Nw,N¢w–dimethyl–L–arginine (SDMA) is also produced but is not an inhibitor
of NOS. Interestingly, elevated plasma ADMA concentrations have been recently
recognized as a novel cardiovascular risk factor, as increased ADMA is associated with
hypercholesterolemia, atherosclerosis, hypertension, chronic renal failure, and chronic
heart failure (4, 5).  High ADMA levels are also concomitant with reduced NOS activity






























Figure 1.1 DDAH catalyzed hydrolysis of NMMA and ADMA
Although the exact intracellular concentrations of ADMA and NMMA are not known,
one study of healthy adults revealed a plasma ADMA baseline of 0.4 ± 0.1 mM, while
patients with chronic renal failure had elevated ADMA levels of 0.7 ± 0.1 mM (7).  One
estimate, based on mouse and rat kidney tissue, measures a cytosolic ADMA
concentration of approximately 10 mM (8).  Conversely, reduced ADMA levels
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(approximately 2–fold below baseline) are found in the cerebrospinal fluid of
Alzheimer’s patients, while L-Arg levels remain normal, suggesting NOS is dysregulated
in this disease (9).  The treatment of certain hypotensive disorders with NMMA is also
being explored (10).  The discovery of ADMA and NMMA as endogenous inhibitors of
NOS is an important advance and deserves further research to investigate the interplay
between Nw–methylated arginines and NOS dysregulation.
REGULATION OF ADMA AND NMMA
In mammals, ADMA and NMMA concentrations are regulated by two isozymes
of dimethylarginine dimethylaminohydrolase (DDAH) (EC 3.5.318).  DDAH–1 is found
highly co–expressed with nNOS in neural tissue, and DDAH–2 is found highly
co–expressed with eNOS in heart and placenta, and both isoforms are highly expressed in
the kidney and liver (11).  DDAH thus partially regulates NOS activity by hydrolysis of
ADMA and NMMA, relieving basal inhibition of NOS (12), and making DDAH an
attractive drug target for diseases involving NO overproduction. (DDAH does not
hydrolyze SDMA, which will not be discussed further here.) Inhibition of DDAH could
either allow endogenous ADMA and NMMA to accumulate or allow lower doses of
administered NMMA to effectively regulate NOS.  Conversely, therapeutic treatment
with DDAH might help to lower elevated ADMA levels in hypertensive patients.
Ogawa et al. first identified that mono– and di–asymmetrically Nw-methylated
arginines were metabolites in rats, and subsequently purified DDAH to homogeneity
from rat kidney (13, 14).  DDAH was found to catalyze the hydrolysis of NMMA and
ADMA to L-citrulline and methylamine or dimethylamine, respectively (Figure 1.1) (14).
Soon thereafter, Leiper et al. demonstrated that certain microbes also had DDAH
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encoding genes in what appear to be arginine handling operons (15), which is somewhat
surprising because bacteria are not known to produce methylated arginines.  While the
biological relevance of prokaryotic DDAHs is not yet known, it is interesting to note that
many of the bacteria harboring DDAH genes are also lung pathogens, including
Pseudomonas areuginosa, Legionella pneumophila, and Mycobacterium tuberculosis.
However, gene knockout experiments that test whether DDAH is a virulence factor in
these organisms have not yet been reported.
Shirai et al. used sequence alignments, structural alignments and similar reaction
chemistry, to define a superfamily of enzymes that includes arginine deiminase (ADI),
amidinotransferase (AT), and peptidyl arginine deiminase (PAD)(16).  Murray–Rust et
al. obtained the first structure of a DDAH from Pa areuginosa (PDB 1H70), showing an
overall fold of a barrel comprised of five modules with a bbab structural motif.  The
DDAH fold showed strong structural homology to ADI, AT and PAD, indicating that
DDAH is a structural member of the same guanidine modifying superfamily (17). The
amino acid sequence of Pa DDAH compared to the mammalian isozymes DDAH–1 and
DDAH–2 is only about 23–29% identical but a recent structure of bovine DDAH–1 has
shown the overall fold to be nearly identical (18).  Murray–Rust et al. also proposed a
putative catalytic triad of active–site residues for Pa DDAH consisting of Cys249,
His162 and Glu114, similar to active–site residues found in other superfamily members




There have been some reports regarding the physiological regulation of DDAH
isozymes.  The presence of a reactive cysteine in the active–site of DDAH led Leiper et
al. to explore the possibility that DDAH might be regulated through S–nitrosylation. Pa
DDAH and mammalian DDAH are reversibly inhibited by NO donors in vitro and
DDAH–2 is S–nitrosylated after cytokine induced expression of iNOS in vivo (19).
Through the use of site–directed mutagenesis, Leiper et al. demonstrated that wild–type
Pa DDAH, but not an inactive C249S variant, could be nitrosylated, indicating the
active–site cysteine was modified (19).  Knipp et al. also found that bovine DDAH-1 was
specifically nitrosylated on two cysteine residues, one of which is the active–site
nucleophile (20).  In addition to S–nitrosylation, bovine DDAH–1 can also be regulated
by Zn(II) ion binding. One tightly bound inhibitory Zn(II) ion (Kd ~ 4 nM) is found at the
active–site, which, upon release, activates DDAH (21).  This tightly bound Zn(II) ion was
also found to protect against cysteine modification by NO donors (20). In mammalian
systems DDAH acts to partially regulate NOS by controlling ADMA and NMMA levels
(22), and it appears that feedback inhibiton by NO is also a possible form of regulation






























Figure 1.2 Methyl–arginine cycle
Mono– and di– methylated arginines arise through post–translational methylation of
proteins by PRMTs.  Subsequent proteolysis releases free Nw-methylarginines.  NOS
activity is partly regulated by ADMA and NMMA, concentrations of which are
controlled by DDAH.  DDAH in turn can be nitrosylated, indicating possible regulation
by •NO.  DDAH–catalyzed hydrolysis of ADMA yields L–Cit, which can be returned to
the urea cycle.  AS = argininosuccinate synthetase, ASL = argininosuccinate lyase, OTC
= ornithine transcarbamoylase, SAM = S –adenosylmethionine, SAH =
S–adenosylhomocysteine, L–Cit = L–Citrulline.
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DDAH MECHANISM, ASSAYS, AND INHIBITION
At the onset of this research project, the physiological relevance of DDAH as
modulator of NOS activity was becoming clear.  The structure of Pa DDAH was also an
important advance, indicating that DDAH is a structural member of the
amidinotransferase family, and suggesting a catalytic triad of Cys249, His162, and
Glu114 residues.  However, only limited mutagenesis studies had been reported, and the
reaction mechanism was unclear.  There were also only a few reported inhibitors for
DDAH (22, 23), and a facile method for screening for new inhibitors was not available.
The research reported here has been able to address several of the gaps that
existed at the beginning of this research.  Using the DDAH from Pa aeruginosa as a
model system, we have provided evidence supporting a substrate–assisted reaction
mechanism, and determined the role of the active–site residues Cys249, His162, and
Glu114 during catalysis.  We have also built on these discoveries and identified a
covalent inactivator, as well as a simple continuous method for detecting DDAH activity
and screening potential inhibitors.
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Chapter 2 Characterization of Pa DDAH, substrate specificity, and
covalent intermediate in the reaction mechanism
Introduction
DDAH catalyzes the hydrolysis of NMMA, and ADMA to citrulline and either
methylamine or dimethylamine respectively and belongs to a superfamily of guanidine
modifying enzymes that includes arginine deiminase, amidinotransferase, and peptidyl
arginine deiminase (PAD)(14, 16).  Although the DDAH from Pseudomonas aeruginosa
only has 23-30% amino acid identity with mammalian isozymes, the active site residues
Cys249, and His162 are conserved and Glu114 replaces Asp (Figure 1.1).  Also the
DDAH from Pseudomonas has been far more tractable for over-expression than its
mammalian counterparts, and has resulted in a crystal structure (17), making this
particular enzyme an excellent model to examine the mechanism of DDAH.
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Figure 2.1 DDAH active–site, substrates, and proposed covalent intermediate.
Some members of the amidinotransferase superfamily, such as arginine
deiminase, have been shown to use reaction mechanisms that proceed through a covalent
intermediate using the conserved active site cysteine as a nucleophile (24).  However, the
mechanism of DDAH has had little characterization, and the role of each conserved
active site residue remains to be determined.  The experiments detailed here demonstrate
that the DDAH–catalyzed hydrolysis reaction does proceed through a covalent
intermediate using Cys249 as the active–site nucleophile.  We used alternative substrates,




CONSTRUCTION OF AN EXPRESSION VECTOR FOR PA DDAH
The coding region for Pa DDAH (Protein GI:53727549) was amplified from Pa
aeruginosa (strain PAO1) genomic DNA (ATCC 470850) using two specific end
primers: 5'-CAGGATCCCATATGTTCAAGCACATCATCGCTCG-3' and 5'-
CGGAATTC TCAGAAGCGCAGCGACATG-3' (Sigma-GENOSYS, The Woodlands,
TX). The forward primer contains an Nde I restriction site (underlined) followed by 20
bases corresponding to the coding sequence of the DDAH gene. The reverse primer
contains an Eco RI restriction site (underlined) followed by 16 bases corresponding to the
gene coding sequence. Amplification of the Pa DDAH gene was carried out by PCR
using an MJ Research (Waltham, MA) PTC 200 thermocycler, along with the
aforementioned primers, genomic DNA, dNTPs (New England Biolabs, Beverly, MA),
and Triplemaster PCR reagents (Eppendorf, Westbury, NY) following a temperature
program: 95º C for 5 min, followed by 30 cycles of 95º C for 30 s, 52º C for 30 s, and 72º
C for 1 min, followed by a 3 min hold at 72º C. The PCR-amplified Pa DDAH coding
sequence was then ligated into a pGEM-T vector (Promega, Madison, WI) and
transformed into Escherichia coli DH5aE cells. The resulting plasmid (pTpaoDDAH)
was isolated, and the insert was sequenced to ensure that there were no undesired
mutations. The pTpaoDDAH plasmid and the pET-28a expression vector were
subsequently digested with Nde I and Eco RI restriction enzymes followed by gel
purification and ligation of the digested Pa DDAH coding sequence into the multiple
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cloning site of pET-28a. The resulting plasmid (designated pETpaDH) was transformed
into E. coli DH5a cells for purification and sequencing of the insert.
CONSTRUCTION OF AN EXPRESSION VECTOR FOR C249S DDAH
An!oligonucleotide,!5'–CGGAATTCTCAGAAGCGCAGCGAGCAggaACTGAC
G-3' (Sigma-GENOSYS) that contained an Eco RI restriction site (underlined) and a
mutant codon (lowercase) was designed to introduce a mutation encoding C249S at the
end of the DDAH sequence. Because the desired mutation was near the 3' end of the Pa
DDAH gene, only one PCR was required, using the mutant reverse primer and forward
primer described above with the aforementioned reaction conditions. After Qiaquick
(Qiagen, Valencia, CA) purification of the C249S PCR product, this insert and a pET-28a
expression vector were digested with Nde I and Eco RI, Qiaquick purified (Qiagen), and
ligated together using T4 DNA ligase (Fisher, Pittsburgh, PA). The resulting plasmid
(pET-DH-C249S) was concentrated by pellet paint precipitation (Novagen, San Diego,
CA) and transformed into E. coli DH5aE cells for plasmid amplification and purification.
DNA sequencing of the coding sequence of the C249S insert indicated that there were no
undesired mutations.
OVEREXPRESSION AND PURIFICATION OF WILD-TYPE AND C249S PA DDAH
For expression of wild-type and C249S Pa DDAH, the expression plasmids were
first transformed into E. coli BL21 (DE3) cells. Typically, over-expression of Pa DDAH
was carried out by inoculating 1 L of LB medium containing 30 mg/mL kanamycin with
10 mL of inoculant from a saturated overnight culture and shaking at 37º C.  IPTG was
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added to a final concentration of 0.5 mM when the expression culture reached an OD600
of 0.5, and expression was continued for an additional 4 h. Cells were then harvested by
centrifugation and stored at –20º C. Frozen cell pellets were re-suspended in pET lysis
buffer [10 mM NaH2PO4 buffer, 300 mM NaCl, and 10 mM imidazole (pH 8.0)] at 40
mL of buffer/L of culture. Cell suspensions were sonicated on ice for 2 min with 15 s
burst/rest cycles followed by centrifugation at 23500 * g for 20 min.  Approximately 15
mL of supernatant was then loaded directly onto an 8 mL Ni-NTA affinity resin column
(Qiagen) and washed with 10 column volumes of lysis buffer (see above), followed by 7
column volumes of 50 mM NaH2PO4 buffer, 300 mM NaCl, and 20 mM imidazole (pH
8.0), and finally eluted with 50 mM NaH2PO4 buffer, 300 mM NaCl, and 250 mM
imidazole (pH 8.0). Fractions (3 mL) were characterized by activity and SDS-PAGE. The
wild-type Pa DDAH did not require additional purification, but the C249S variant was
further purified by loading fractions containing the desired protein onto a DEAE ion-
exchange column. This column was washed with 20 mM Tris-HCl buffer (pH 8.0), and
then purified protein was eluted stepwise by the addition of a mixture containing 75% of
20 mM Tris-HCl buffer (pH 8.0) and 25% of 20 mM Tris-HCl buffer and 1 M NaCl (pH
8.0).  Fractions were characterized by SDS-PAGE, and those containing purified protein
were pooled. To remove any extraneously bound metal ions, purified proteins were
dialyzed overnight at 4º C in 4 L of 2 mM 1,10-phenanthroline and 100 mM KCl (pH 7),
followed by two 4 h dialyses composed of 4 L each of Chelex-100-treated (Bio-Rad,
Hercules, CA) 10 mM MES and 100 mM KCl at pH 6.2 and 4º C. The final purification
products were made 10% in glycerol and stored in aliquots at –80º C after being flash-
frozen in liquid N2.
13
CHARACTERIZATION OF PA DDAH
The first 15 N-terminal residues of purified wild-type Pa DDAH were sequenced
by Edman degradation at the Protein Facility (Institute for Cellular and Molecular
Biology, The University of Texas).  To determine the final metal content, a protein
sample (79 mM) and associated dialysis buffer were analyzed by inductively-coupled
plasma mass spectrometry (ICP-MS, Department of Geological Sciences, The University
of Texas) to quantify the protein's zinc content by subtracting the concentration of zinc
found in dialysis buffer from the zinc concentration of the final protein sample and
dividing by the protein concentration. To determine protein concentrations, an extinction
coefficient was calculated for Pa DDAH on the basis of the amino acid sequence
(http://workbench.sdsc.edu/) (25). All protein concentrations for DDAH were calculated
on the basis of the calculated e280 of 17 210 M–1 cm–1 in a final buffer concentration of
6!M guanidinium hydrochloride and 20 mM phosphate buffer (pH 6.5).
MASS SPECTRUM ANALYSIS OF PRODUCTS FORMED IN THE DDAH REACTION
Because the standard colorimetric assay used for citrulline (26) detects ureido
groups and is not specific for citrulline formation (27), mass spectrometry was used to
establish the reaction products of Pa DDAH. A Sephadex G-10 spin column was used to
exchange a sample of enzyme into 25 mM ammonium bicarbonate buffer (pH 7). An
amount (1 mmol) of ADMA was then incubated overnight with 375 pmol of Pa DDAH in
25 mM ammonium bicarbonate buffer (pH 7). The subsequent reaction products were
analyzed by MALDI-TOF. Two control samples, one lacking enzyme and one lacking
substrate, were also analyzed on an Applied Biosystems (Foster City, CA) Voyager-DE
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PRO mass spectrometer using a-cyano-4-hydroxycinnamic acid as the matrix as
previously described (12).
STEADY-STATE KINETIC STUDIES
Using a slightly modified published protocol (28) that detects formation of a
ureido group, the steady-state catalytic rate constants of Pa DDAH were determined for
hydrolysis of various compounds, including creatine, creatinine, argininosuccinate,
guanidinoacetate, L–arginine, L–homoarginine, L–canavanine, N-amino- L-arginine, Nw-
hydroxy–L-arginine, Nw-methyl–L-arginine (NMMA), Nw,Nw-dimethyl–L-arginine
(ADMA), and S-methyl–L-thiocitrulline (SMTC) (Sigma-Aldrich Chemical Co., St.
Louis, MO). Typically, substrate concentrations ranging from 78 mM – 10 mM were
prepared by serial dilution in an assay buffer consisting of Na2HPO4 (100 mM) buffer (pH
6.2). Substrate aliquots of 200 mL were placed in 1.5 mL microcentrifuge tubes to which
5 mL of a 79 mM enzyme stock was added. Most reactions were carried out at 25º C for 1
min, and then stopped by addition of 10 mL of 6 N trichloroacetic acid (TCA). Control
reactions showed that citrulline production under these conditions is linear for more than
5 min.  Slower substrates such as L-arginine were assayed at 25º C for longer periods of
time (2 h) with increased enzyme concentrations (4.5 nM). Compounds that displayed no
turnover were further tested at 25º C for activity by incubating each compound (5 mM)
with a higher concentration of enzyme (6 mM) for 1 h. A control reaction without the
enzyme was also performed at each substrate concentration, enabling background
citrulline levels to be subtracted. A series of standards for quantifying final citrulline
concentrations was prepared by serially diluting citrulline to a final concentration range
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of 0-313 mM in 100 mM Na2HPO4 buffer (pH!6.2) and aliquoting these samples in 200
mL portions in 1.5 mL microcentrifuge tubes. To the citrulline standards, enzyme reaction
mixtures, and controls was added 1 mL of freshly prepared color-developing reagent
(28), and the tubes were placed in a boiling water bath for 15 min and then cooled for 10
min at 25 C. The absorbance at 540.5 nm was measured for each sample using a Cary 50
UV-vis spectrophotometer (Varian Inc., Walnut Creek, CA) and then converted into
citrulline concentrations by using a standard curve. The resulting data, after background
subtraction, were fit directly to the Michaelis–Menten equation using KaleidaGraph
(Synergy Software, Reading, PA). All reactions were carried out in at least triplicate.
Activity tests for the C249S variant were also performed using 10 mM substrates
(NMMA, ADMA, and SMTC) for 1 h at 37º C to maximize the chance of detecting any
citrulline that might be formed.
MASS SPECTRUM ANALYSIS OF COVALENTLY MODIFIED PA DDAH
To characterize a covalent enzyme-substrate intermediate that might accumulate
during steady-state reactions, incubations of NMMA, ADMA, or SMTC and DDAH were
quenched with acid during turnover. Samples were typically prepared by incubating
20–60 mM enzyme and 10-45 mM substrate in 10 mM MES buffer, 100 mM KCl, and
10% (v/v) glycerol (pH 6.2) at 25º C, followed by quenching with 1 M trifluoroacetic
acid to a final concentration of 83 mM after reaction for 0, 1, 5, and 30 min. A control
lacking substrate was included for every reaction. Samples were then desalted on a
protein trap (Protein MicroTrap, Michrom, Auburn, CA) and analyzed by electrospray
ionization mass spectrometry (ESI-MS) on a ThermoFinnigan LCQ (San Jose, CA) ion
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trap mass spectrometer as described previously (29) using a 10 min 5 – 95% B gradient
delivered by a Michrom Magic 2002 HPLC system.
IDENTIFICATION OF COVALENTLY MODIFIED PEPTIDE
Steady-state reaction mixtures of Pa DDAH and SMTC were prepared and the
reactions quenched with acid as described above. A Sephadex G–10 spin column was
then used to exchange these reaction mixtures into 50 mM ammonium acetate buffer (pH
4) where the covalent adduct is stable (data not shown) and where an acid stable protease
would be active. The resulting product was subsequently digested with Glu–C
endoproteinase (Roche, Indianapolis, IN) in a 20:1 (w/w) ratio for 18 h at room
temperature. Digestion products were analyzed using MALDI-TOF and MALDI-PSD on
an Applied Biosystems Voyager-DE PRO system using a-cyano-4-hydroxycinnamic acid
as the matrix as previously described (30). Theoretical digest masses were calculated
with MS-Digest in the Protein Prospector suite using two missed cleavages (31).
Results
EXPRESSION AND CHARACTERIZATION OF WILD-TYPE AND C249S PA DDAH
The Pa DDAH coding sequence was amplified from genomic DNA and cloned
into a pET-28a expression vector without any undesired mutations. The resulting N-
terminal His6-tagged protein was overproduced in BL21 (DE3) E. coli, and a single
affinity chromatography step resulted in homogeneous wild-type Pa DDAH (>98%
homogeneous) as assessed by SDS-PAGE.  Characterization of the purified protein by
ESI-MS showed a major peak at 30 495 ± 10 Da, which matches (within error) the mass
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calculated from the amino acid sequence (30 503 Da) of His6-tagged Pa DDAH when the
N-terminal methionine residue had been removed (Figure 1A).  The first 15 amino acids
of the purified protein were identified by N–terminal sequencing to give a
GSSHHHHHHSSGLVP sequence, confirming that the N–terminal methionine had been
removed. ESI-MS of protein samples gauged to be homogeneous by SDS-PAGE did
reveal a minor peak that carries an additional 177 ± 10 Da adduct and a small peak
indicating an additional 254 ± 10 Da adduct, both of which are consistent with a minor
fraction of the purified DDAH carrying a nonenzymatic modification at the N-terminus
from a-gluconoylation and a-6-phosphogluconoylation, respectively, both of which have
previously been characterized in other recombinant proteins containing polyhistidine tags
(32). The total amount of gluconoylation varied among enzyme preparations, but was
always only a minor component. The modified and unmodified N-terminal His6 tags were
not removed for these tests because the crystal structure of this enzyme places the N-
terminus distant from both the active site (17) and the dimer interface (33), the His6
fusion was previously shown to be active (15), and short N-terminal extensions of other
DDAH isoforms do not significantly affect their kinetics (34). Unlike the wild-type
protein, the C249S variant required an additional purification step.  Hence, ion-exchange
chromatography followed the initial affinity column and resulted in >95% purity as
assessed by SDS-PAGE. Because zinc has been shown to inhibit the activity of bovine
brain DDAH (21, 35), chelation and dialysis steps were carried out at the end of the
purification to remove any remaining zinc ions. For both the wild type and the C249S
variant, less than 0.001 equiv. of zinc was found in the final purified proteins.
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MASS SPECTRAL ANALYSIS OF SUBSTRATE DIGESTION PRODUCTS
The substrate ADMA was completely hydrolyzed by purified DDAH, and the
reaction products were analyzed by MALDI-TOF. A control reaction, lacking enzyme,
was used to determine the mass of unhydrolyzed ADMA: M·H+ obs , 203.1 ± 0.1 Da;
M·H+ calc, 203.14 Da. MALDI-TOF of reaction mixtures in which ADMA was incubated
with purified DDAH showed a loss of this 203.1 Da peak and the appearance of two new
peaks at 46.0 ± 0.1 and 176.1 ± 0.1 Da, corresponding to the calculated masses of
dimethylamine (M·H+ calc , 46.06) and citrulline (M·H+ calc , 176.10).
DETERMINING THE STEADY-STATE KINETIC CONSTANTS
An established discontinuous assay for citrulline production (28) was used to
follow any hydrolysis reactions observed with varying concentrations of different
compounds as catalyzed by the purified wild-type Pa DDAH (Table 2.1 ). This enzyme
was shown to prefer ADMA over NMMA (indicated by a 3.9-fold increase in kcat/KM),
but the artificial substrate SMTC had the highest kcat (1.5-fold increase) and the lowest KM
(2.2-fold decrease) of all of the substrates that were tested. An apparent substrate
inhibition was observed with NMMA, ADMA, Nw–hydroxy–L-arginine, and
Nw–amino–L–arginine at concentrations above 10 mM, but SMTC did not show any
substrate inhibition at concentrations up to 40 mM (data not shown).  Further experiments
will be required to determine the mechanism of substrate inhibition, so concentrations of
<10 mM were typically used for these studies.
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Table 2.1 Steady-state Rate Constants for DDAH-Catalyzed Hydrolysis of Substrates,
Ranked by Increasing kcat/KM Values
Substrate kcat (min-1) KM (mM) kcat/KM (min-1 mM-1)
L-Arginine a 0.10 ± 0.02 940 ± 50 0.11 ± 0.03
Nw-Amino-L-arginine a 7.2 ± 0.1 1110 ± 60 6.5 ± 0.4
Nw-Hydroxy-L-arginine a 20 ± 2 2300 ± 400 9 ± 2
NMMA (1); Rat DDAH b 5.6 360 ± 10 16
NMMA (1) a 18.6 ± 0.6 670 ± 60 28 ± 3
ADMA (2); Rat DDAH b 9.2 180 ± 10 51
ADMA (2) a 33.6 ± 0.6 310 ± 20 108 ± 9
SMTC (3) a 50.4 ± 0.6 143 ± 5 350 ± 20
a.  Reactions are carried out with Pa DDAH at 25o C and at pH 6.2.
b.  Values are from (14), and were carried out with rat kidney DDAH at 37o C and at pH
6.5.
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Less active substrates include N-hydroxy- L-arginine, N-amino- L-arginine, and L-
arginine that have kcat /KM values 8-, 17-, and 1000-fold lower, respectively, than that of
ADMA. Creatine, creatinine, argininosuccinate, guanidinoacetate, L-homoarginine, and
L-canavanine were not good substrates, exhibiting either no activity or less activity than
L-arginine. We were unable to detect any activity for the C249S variant-catalyzed
hydrolysis of compounds (NMMA, ADMA, and SMTC) under the conditions described
above, indicating that the kcat of this variant must be lowered by at least 5 orders of
magnitude.
MASS SPECTROMETRY OF ACID-QUENCHED STEADY-STATE REACTIONS
To obtain evidence for a transient covalent adduct, reactions were acid-quenched
at various time points before, during, and after turnover and then analyzed by ESI-MS.
The deconvoluted mass spectrum of a control reaction, quenched before addition of
substrate, results in a major peak at 30 495 ± 10 Da (Figure 2.2 A) matching that of
unmodified Pa DDAH (see above). The minor peak seen at 30 672 Da is assigned to the
fraction of DDAH with a-gluconoylation at the N-terminus. Analysis of a steady-state
reaction between SMTC and DDAH that was quenched after 1 min of turnover clearly
shows that the major peak shifts 158 Da higher to 30 653 ± 10 Da, with only a minor
amount of the unmodified 30 496 Da peak remaining (Figure 2.2 B).  The small peak due
to the fraction of enzyme that is a-N-gluconoylated also shifts an equivalent amount (156
± 10 Da) and maintains a similar ratio to the major peak throughout the reaction. A
reaction quenched after 5 min of turnover (Figure 2.2 C) results in essentially the same
peaks that are seen in the 1 min sample, but the relative peak heights of the major peak
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(30 654 Da) and the unmodified enzyme peak (30 495 Da) have changed, showing an
increase in the unmodified enzyme peak after reaction for 5 min.  Finally, after a 30 min
reaction (Figure 2.2 D), the spectrum does not show any peaks different from those
observed in the starting sample (Figure 2.2 A).
The progress curve for Pa DDAH–catalyzed conversion of SMTC (20 mM) to
citrulline was determined for a reaction using the same conditions that were used for
preparing the ESI-MS samples described above (Figure 2.2 E). It should be noted that
these experiments involve much more enzyme than is normally used when measuring
initial rates. Citrulline is produced at the highest rate during the first 1 min, which
corresponds to the ESI–MS spectrum showing the largest 158 ± 10 Da adduct peak
(Figure 1B). After the reaction has progressed for 5 min, the rate of citrulline production
is slowed, most likely due to product inhibition (36) under these conditions, and
corresponds to the ESI-MS spectrum in which less of the 159 ± 10 Da adduct is seen
relative to the unmodified enzyme (Figure 2.2 C). Finally, after 30 min, the reaction
slows because the conversion of SMTC to citrulline is nearly complete, and this
corresponds to the ESI-MS spectrum (Figure 2.2 D) that is nearly identical to that taken
before the reaction was started (Figure 2.2 A). In short, a covalent adduct of 158 ± 10 Da
transiently appears during Pa DDAH-catalyzed turnover of SMTC. The ratio of this
adduct to the unmodified enzyme is the largest during the fastest initial hydrolysis rates,
decreases when less enzyme is available to react with the substrate (probably due to
product inhibition), and disappears when the conversion is complete.
Despite its lack of activity, the C249S variant was also tested for possible
formation of a covalent adduct upon incubation with SMTC.  ESI-MS of the quenched
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incubations only showed one major peak at 30 481 ± 10 Da, consistent with a calculated
mass of 30 487 Da for the C249S variant after removal of the N-terminal methionine.
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Time (min)
Figure 2.2 Deconvoluted ESI-MS of quenched DDAH reactions with S-methyl-L-
thiocitrulline (SMTC)
Reactions are acid-quenched before (A) and after addition of SMTC with subsequent
turnover for (B) 1, (C) 5, and (D) 30, min. The minor peaks that consistently contain a
178 Da adduct throughout the reaction reflect a fraction of the enzyme that is a-N-
gluconoylated during expression (32). (E) A progress curve showing hydrolysis of SMTC
(20 mM) to citrulline under the same conditions that were used for the trapping
experiments in panels A-D indicates that the fastest rate of hydrolysis corresponds with
the sample containing the most 157 Da adduct and that, after turnover is finished, the
enzyme does not contain this 157 Da adduct.
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IDENTIFICATION OF THE COVALENTLY MODIFIED PEPTIDE
To determine both the residue that is transiently modified and a more precise
mass of the covalent adduct, an acid-trapped reaction mixture containing both the
unmodified enzyme and the enzyme containing the 158 Da adduct was digested by Glu-C
endoproteinase and the resulting peptides were detected by using MALDI-TOF in both
linear and reflectron modes. The theoretical digest peptide molecular masses were
compared to the observed MS data, and 24 different peptides covering 74% of the total
sequence were successfully detected, including peptides containing active site residues
Cys249, His162, Glu114, and Thr165 (Table 2.2).  An N-terminal peptide was detected
and corresponds to the mass of the first 52 residues without the N-terminal methionine,
again showing removal of the N-terminal methionine during expression and purification
of His 6-tagged Pa DDAH. A minor peak corresponding to this same N-terminal peptide
but with an additional 178 ± 1 Da was also observed, consistent with a small amount of
DDAH undergoing nonenzymatic N-terminal a–gluconoylation during expression as
reported with other recombinant proteins (32). A small amount of a 258 Da adduct to this
peptide was also observed (data not shown) in our samples, consistent with the presence
of a very minor fraction of an a-N-6-phosphogluconoyl modification usually found in
small amounts when this nonenzymatic gluconoylation occurs during overexpression
(32).
Importantly for the detection of a covalent adduct, the linear MALDI spectrum of
the digestion mixture shows a peptide at m/z 1732.9, corresponding to the average mass
of  the C-terminal  DDAH peptide fol lowing Glu-C cleavage
(240YRKIDGGVSCMSLRF254). This C–terminal peptide contains the active site Cys249
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residue. The same spectrum also shows a peptide at m/z 1890.2, which does not
correspond to the mass of any predicted DDAH Glu-C cleavage peptide, but is 157.3 ±
0.4 Da higher than the DDAH C-terminal peptide mass. This postulated adduct is
consistent with the 158 ± 10 Da adduct found when the undigested protein was analyzed
by ESI-MS. The peptide at m/z 1890 is not seen in the MALDI reflectron spectrum,
demonstrating that it contains a bond that readily fragments after ionization. No mass
increase was found for any of the 23 other peptides found in the digest. Comparison of
the C–terminal adduct to the ESI-MS results of the intact protein indicates that there is
just a single modification, excluding the missing peptides in the digest as sites for
multiple attachments.
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To identify the modified residue, ions from the MALDI post source decay (PSD)
fragmentation spectra of both the native C-terminal peptide at m/z 1733 and the modified
peptide at m/z 1890 were compared (Table 2.2). Immonium ions, b ions, and y ions (see
ref (37) for nomenclature) from each parent confirm that both peptides are derived from
the same amino acid sequence. The primary fragments for the m/z 1733 peptide are b5
and y10 ions produced by fragmentation after an Asp residue. The m/z 1890 peptide
undergoes a dominant fragmentation involving neutral loss of 157 and 190 Da to produce
the m/z 1733 and 1700 fragments, respectively, consistent with fragmentation on either
side of a sulfur atom (Figure 2.3).  The sum of these observations shows that
modification occurs at the only cysteine residue found within this peptide, Cys249.
27
Table 2.2 Summary of Proteolytic Cleavage of DDAH with Glu-C Endoproteinasea
DDAH Sequence #











































240-254 + IMOd 1890.2 1890.3
a Comparing calculated peptide masses (MS-Digest in Protein Prospector) with
experimental results by MALDI-TOF for digestion with up to two missed cleavages.
Amino acid numbering is assigned to match that of 1H70.pdb (17).
b  Mass accuracy is 200!ppm.
c aGlc stands for N-terminal a-gluconoylation (32).
d IMO stands for the 1-(iminomethyl)-L-ornithine fragment of the covalent adduct
(Figure 2.3 B).
* Denotes monoisotopic mass.
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Figure 2.3 Fragmentation patterns from MALDI-PSD
(A) The 1733 Da peptide shows y14, y10, b2, and b5 fragments. (B) The 1890 Da peptide
shows the same b5 fragment, but y14 and y10 also contain an additional adduct.




 DDAH plays an important role in regulating endogenous pools of the NOS
inhibitors ADMA and NMMA in mammals, so understanding its catalytic mechanism is
of significant interest.  Why a bacterium that is not known to produce methylated
arginines has a DDAH gene is not yet well understood.  However this enzyme will serve
as a model system for investigating the mechanism of DDAH.  The colorimetric assay
used to determine activity is not specific to citrulline alone (27), so we sought to
determine the actual reaction products to ensure that Pa!DDAH is the functional
equivalent of the mammalian isozymes.  For a counter example, instead of the
Nw–nitrogen, related amidinotransferases in the same superfamily use the ornithine side
chain rather than dimethylamine as the leaving group (38).  If Pa DDAH breaks a similar
bond in its NMMA substrate, the resulting reaction products would be L–ornithine and N-
methylurea, which would be indistinguishable from citrulline when using the colorimetric
assay.    In order to rule out this possibility, MALDI–TOF–MS was used to characterize
the reaction products after complete hydrolysis of ADMA by purified Pa DDAH.  The
MS analysis identified citrulline and dimethylamine as two new products, unambiguously
identifying dimethylamine as the leaving group in the reaction catalyzed by this bacterial
enzyme and demonstrating that the products are the same as those found with the
mammalian DDAH enzymes (14).  There was no evidence of either L–ornithine or N-
methylurea being formed.
Having established the reaction products, the steady-state kinetic constants for Pa
DDAH catalyzed hydrolysis were determined for a variety of common guanidino-
containing compounds by using a published discontinuous diacetyl monoxime
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derivatization assay (28).  Supporting the proposition that this enzyme is a true DDAH,
asymmetric methylated arginine analogs are shown to be the preferred substrates (Table
1).  In fact, the kcat/KM values for hydrolysis of ADMA and NMMA are both nearly 2-fold
higher than those reported for mammalian DDAH isolated from rat kidney (Table 1) (14).
ADMA is the preferred substrate for Pa DDAH (15) as reflected in a 1.8–fold increase in
kcat and a 2.1-fold decrease in KM when compared to NMMA.  A similar result to that of
rat kidney DDAH which shows a 1.6-fold increase in kcat and a 2.0-fold decrease in KM
when comparing ADMA and NMMA as substrates (14).  The presence of an N w-
substitution appears to be important for catalysis.  Nw-hydroxy-L-arginine and Nw-amino-
L-arginine are moderate substrates, but L-arginine is a very poor substrate with a kcat/KM
value three orders of magnitude lower than that of ADMA. Interestingly, the NOS
inhibitor SMTC (39) proved to be the best substrate tested so far with a 2.7-fold faster kcat
and 4.7 fold lower KM at pH!6.2 as compared with its natural analog NMMA.
 Other guanidino compounds commonly found in metabolism are not effectively
processed as substrates, further supporting the proposed function of this enzyme as a
DDAH.  Despite the lack of known methyl arginine production in Pseudomonas sp., the
observation that ADMA is a preferred substrate, and the determination that reaction
products and rate constants are comparable to a known mammalian DDAH enzyme, are
consistent with the assignment of this bacterial enzyme as an authentic DDAH.
Two other guanidino modifying enzymes in the superfamily, arginine deiminase
(24, 40) and arginine:glycine amidinotransferase (41, 42), have been shown to utilize a
covalent intermediate in their reaction mechanisms.  The amidinotransferase reaction was
studied through the use of radiolabeled L-arginine and acid trapping, and the arginine
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deiminase reaction was elucidated through acid trapping, pre-steady-state kinetics (24)
and X-ray crystallography (43).  In a similar fashion we attempted to acid trap a transient
covalent intermediate formed during steady-state turnover with the naturally occurring
substrates ADMA and NMMA, but only found a single peak by ESI-MS with the same
mass as unmodified enzyme.  We hypothesized that either the rate of intermediate
formation was rate determining thus limiting detectable amount of adduct, or that the
DDAH catalyzed reaction does not use a covalent intermediate in its mechanism.  A non-
covalent mechanism would not be totally be unprecedented because at least one
guanidino hydrolase, creatine amidinohydrolase, uses histidine as a general base to
generate a hydroxide nucleophile (44).  We then tried acid trapping with the substrate
analogue SMTC, which has a 1.5 fold higher kcat than ADMA (Table 2.1). Reactions of
SMTC turnover by Pa DDAH were quenched at different time points to trap any covalent
intermediate that accumulates.  Points were taken throughout an entire progress curve at
0, 1, 5, and 30 min to insure that any adduct observed is transient in nature, and not the
result of time-dependent inactivation.  In contrast to our results with methylated
arginines, the ESI-MS of a reaction mixture after 1 min of turnover (Figure 2.1B) showed
appearance of a new major peak, indicating the formation of a new covalent adduct of
158 ± 10 Da (Figure 1B).    The mass of this adduct is consistent with the expected mass
increase (157.09 Da) after loss of a proton from an amino acid side chain and formation
of a covalent bond between Pa DDAH and the remaining 1-(iminomethyl)-L-ornithine
portion of the SMTC substrate after loss of its methanethiol leaving group.  After 5 min
of turnover (Figure!2.1C) the major peak is still that of the 158 Da adduct, but the amount
of free enzyme has increased, and after 30 min of turnover (Figure 2.1D) the major peak
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has returned to all free enzyme.  A progress curve following citrulline production was
taken under identical conditions as the acid-trapping experiment (Figure 2.1E) and shows
that the rates observed parallel the relative amounts of enzyme-intermediate observed by
ESI–MS in Figure 2.1 A–D.  (For both the progress curve and the acid-trapping
experiments, enzyme concentrations are much higher than those commonly used for
determining initial rates.)  Unrelated to the transient covalent adduct, a constant minor
peak resulting from an N-terminal 178 Da adduct is seen at all time points and is due to
non-enzymatic a-gluconoylation of the protein during expression (32);  the ratio of this
+!178 Da peak to the major peak is constant throughout the entire progress curve,
providing further evidence that small differences in the N-terminus do not have
significant catalytic consequences.
In order to map out the site of the covalent adduct, quenched reactions were
digested with Glu–C endoproteinase at pH 4 where the S–alkylthiouronium intermediate
is expected to be stable.  This digest was analyzed by MALDI–TOF, resulting in 24
observed peptides covering 74% of the total sequence, including peptides containing the
active site residues Cys249, His162, Glu114 and most of the other residues within 6 Å of the
ureido group of citrulline complexed with Pa DDAH (17). MS analysis was able to
identify 24 different peptides covering 74% of the total sequence, including peptides
containing the active site residues Cys249, His162, and Glu114.  The linear MALDI spectrum
of the digestion mixture shows a peptide at m/z 1732.9, corresponding to the average
mass of the C -terminal DDAH peptide following Glu–C cleavage
(240YRKIDGGVSCMSLRF254). This C -terminal peptide also contains the active–site
Cys249 residue.  The same spectrum also shows a peptide at m/z 1890.2, which does not
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correspond to the predicted mass of any DDAH Glu-C cleavage peptide, but is 157.3 Da
higher than the DDAH C -terminal peptide mass, consistent with the proposed
intermediate.  The peptide at m/z 1890 is not seen in the MALDI reflectron spectrum,
demonstrating that it contains a bond that readily fragments after ionization, such as
would be expected for a sulfide–carbamide bond. No increase of 157 Da was found for
any other peptides in the digest.  The immonium ion, b and y ions for the adducted
peptide are similar to those of the unmodified peptide, confirming that the same peptide
sequence is involved in both cases.  The adducted peptide PSD shows modified y10* ions
that appear as a pair of peaks separated by 34 Da.  They represent dual fragmentation
products with both backbone fragmentation and loss of the unstable adduct, again
fragmenting on either side of the sulfide bond and implicating Cys249 as the point of
attachment (Figure 2.3).
To corroborate the importance of Cys249, a C249S mutation was constructed and
purified.  A crystal structure of this variant shows that it folds properly and is capable of
binding substrate (17).  This mutant enzyme does not hydrolyze NMMA, ADMA, (17)
nor SMTC, and acid quenched mixtures of SMTC and C249S only resulted in one major
peak by ESI–MS, with a mass matching that of unmodified mutant enzyme.
Together these results show that the Pa DDAH is indeed a member of the
superfamily of guanido modifying enzymes.  Despite their being no evidence for
Pseudomonas species that can produce methyl arginines, this bacterium is shown to have
a gene product capable of catalyzing the identical reaction chemistry, and similar
substrate specificity as its mammalian counterparts.  The use of the activated substrate
analogue SMTC, reveals that, like arginine deiminase and arginine:glycine
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amidinotransferase,  the DDAH catalyzed reaction proceeds through attack of an
active–site cysteine nucleophile, forming a transient S–alkylthiouronium intermediate,
and  thus further relating it to the superfamily of guanido modifying enzymes.  The
mechanistic information from the experiments detailed here will greatly facilitate design
of inhibitors for DDAH and perhaps other superfamily members that are potential drug
targets.
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Chapter 3 A New Continuous Assay for DDAH Activity and
Quantification of Product Inhibition
Introduction
Dimethylarginine dimethylaminohydrolase (DDAH) is found in both prokaryotes
and eukaryotes and catalyzes the hydrolysis of Nw-methyl-L-arginine (NMMA, Scheme
3.1 A) and asymmetric Nw,Nw–dimethyl–L–arginine (ADMA) to L-citrulline and either
methylamine or dimethylamine, respectively (14, 15, 45).  In mammalian systems,
ADMA and NMMA are endogenous inhibitors of nitric-oxide synthase, making DDAH
an attractive target for therapeutic intervention because of its regulation of nitric oxide
production through control of ADMA and NMMA concentrations (12).  To date, the only
reported methods for monitoring DDAH activity have been discontinuous assays.  The
use of radiolabeled substrates (13), HPLC (46), or derivatization to detect dimethylamine
production (47) have been reported, but the most commonly used procedure to assay
DDAH activity relies on diacetyl monoxime (DAMO) derivatization of the ureido group
in L-citrulline (Scheme 3.1 A) to form a colored product (26, 27).  This assay has been
optimized for monitoring DDAH activity in a 96-well format (28), but still requires
several laborious steps that can introduce error and hazard, including the addition of
strong acids and prolonged incubation of sealed tubes or microtiter plates at 95º C.  This
method also suffers from the instability of the final chromophore to light (26), the
inability to distinguish L-citrulline from other compounds that have ureido groups, and
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the discontinuous nature of the assay which requires approximately 25 min to develop






















Scheme 3.1 DDAH catalyzed reaction products of NMMA and SMTC
We therefore developed a new assay for DDAH activity based on the use of the
alternative substrate, S-methyl-L-thiocitrulline (SMTC), that, upon hydrolysis, is
proposed to produce methanethiol (Scheme 3.1 B) which can easily be quantified by 5,5’-
dithiobis(2-nitrobenzoic acid) (DTNB) in a continuous spectrophotometric assay.
Because of the similar reactions catalyzed by this superfamily of enzymes, it is likely that
this strategy could be more widely applied.
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This alternative substrate, SMTC, is commercially available (Sigma-Aldrich
Chemical Co., St. Louis, MO), and similar in structure and charge (the pKa of S -
methylthiourea is 9.8 (48)) to NMMA (the pKa of N,N’-dimethylguanidine is 13.6 (48)), a
natural substrate of DDAH.  Previous studies (Chapter 2) using the DAMO assay
demonstrated that SMTC serves as a good substrate for the DDAH from PA aeruginosa,
and that this bacterial DDAH which shares 29-30 % amino acid identity with human, rat
and bovine DDAH-1, and 23% identity with human and rat DDAH-2, processes NMMA
and ADMA with comparable rates to those reported for mammalian DDAH isozymes
(14, 35, 49).  In this study we compared the kinetics of DDAH–catalyzed hydrolysis of
SMTC as assayed by the discontinuous DAMO derivatization assay to follow L-citrulline
production, and as assayed using DTNB to follow methanethiol production in a
continuous spectrophotometric assay.  We also demonstrated the utility of this new assay
method by determining the Ki of product inhibition by L-citrulline, a measurement not
readily made using the DAMO derivatization assay.
Materials and Methods
STEADY–STATE KINETICS OF SMTC HYDROLYSIS AS DETERMINED BY DAMO
DERIVATIZATION ASSAY
The DAMO derivatization assay for L–citrulline production (28) was used, with
minor modification, to determine the  kcat and KM values for SMTC hydrolysis by Pa
aeruginosa DDAH (49) under the same conditions as used for the continuous assay
described below.  Briefly, concentrations of SMTC (0 – 10 mM) were prepared in assay
buffer consisting of 0.1 M phosphate buffer, pH 7.27, containing 1 mM EDTA to chelate
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any trace metals that could catalyze unwanted thiol oxidation.  Substrate aliquots of 200
mL were placed in 1.5 mL microcentrifuge tubes to which 5 mL portions of a stock
solution of purified recombinant His6-DDAH from PA aeruginosa (79 mM) (49) were
added to initiate the reactions.  Substrate and enzyme were incubated at 25º C for 1 min
and then quenched with 10 mL of trichloroacetic acid (6N) to stop the reaction.  Control
reactions without enzyme were included for each substrate concentration.  Standards
containing L–citrulline (0 to 313 mM) were also prepared in 0.1 M phosphate buffer, 1
mM EDTA, pH 7.27, and used to construct a linear standard curve.  To the standards and
quenched reactions, a 1 mL aliquot of a color developing reagent containing DAMO and
other components (28) was added.  Reaction tubes were sealed and placed in a boiling
water bath for 15 min, and then cooled to 25º C over a 10 min period.  The absorbance at
540 nm was measured for each sample using a Cary 50 UV-Vis spectrophotometer
(Varian Instruments, Walnut Creek, CA).  The resulting absorbance values, after
background correction, were converted to L-citrulline concentrations using a standard
curve and the initial rates of product formation at each substrate concentration were fit
directly to the Michaelis-Menten equation (Kaleidagraph; Synergy Software, Reading
PA).
STEADY–STATE KINETICS OF SMTC HYDROLYSIS AS DETERMINED BY CONTINUOUS
ASSAY
The steady-state DDAH-catalyzed hydrolysis of SMTC was measured, but instead
of the discontinuous assay, DTNB was used to monitor methanethiol release in a
continuous manner.  Briefly, stock concentrations of SMTC (0 - 10 mM) were prepared
in assay buffer containing 0.1 M phosphate buffer, 1 mM EDTA, pH 7.27 and a stock
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solution of DTNB (5 mM), as described (50).  To a microcuvette, 300 mL of a substrate
stock and 10 mL of DTNB reagent were mixed and the reaction was initiated by the
addition of 2.5 mL of enzyme stock (79 mM).  Changes in absorbance at 412 nm were
monitored continuously.  At 10-fold lower enzyme concentrations and sufficient substrate
and DTNB concentrations, increases in absorbance due to substrate hydrolysis were
found to be linear for times longer than 10 min, indicating that, despite the five cysteine
residues found in Pa DDAH, enzyme activity is not adversely effected by incubation with
DTNB on this timescale.  Similar incubations at 37º C were also linear, but showed some
loss of activity at times longer than 6 min, suggesting that at increased temperatures, this
enzyme is more susceptible to modification by DTNB.  Typically, after a short initial
mixing period (less than 20 s) reactions were followed at 25º C for 2-5 min and the linear
portions of the curves were plotted to obtain an observed rate for hydrolysis of SMTC at
each concentration. These observed steady-state rates (AU/min) were converted to units
of mM/s using a published molar absorption coefficient of 14,150 M-1 cm-1 (50).  This
extinction coefficient is sensitive to pH, temperature, and some other experimental
conditions (50-53), so these must be carefully controlled.   The resulting data were fit
directly to the Michaelis-Menten equation as described above (Figure 3.1, inset).
COMPETITIVE INHIBITION OF DDAH BY L-CITRULLINE WITH THE CONTINUOUS
ASSAY
Briefly, assay solutions were prepared containing varying SMTC (9 - 313!mM)
and L-citrulline (1.2 - 17 mM) concentrations, all in 1 mM EDTA, 0.1M phosphate
buffer, pH 7.27.  To a microcuvette, 290 mL of a substrate / inhibitor mixture and 10 mL
of the DTNB reagent were mixed, and the reaction was initiated by the addition of 2.5 mL
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from an enzyme stock solution (79 mM).  Production of methanethiol and its subsequent
reaction with DTNB was monitored continuously at 412 nm as described above.
Results
STEADY–STATE KINETICS OF SMTC HYDROLYSIS AS DETERMINED BY DAMO
DERIVATIZATION AND BY CONTINUOUS ASSAY
These two dissimilar assay methods for steady-state hydrolysis of SMTC by
DDAH gave comparable results and these data were well fit by the Michaelis-Menten
equation.  The steady-state rate constants were found to be consistent whether measured
by the discontinuous DAMO assay that follows L-citrulline production (KM = 23 ± 3 mM;
kcat = 48.6 ± 0.6 min-1) or by the DTNB detection of methanethiol release (KM = 19 ± 1
mM; kcat = 72 ± 0.6 min-1).  These results illustrate that a continuous assay for DDAH can
be easily used for quantifying the catalytic activity of this enzyme and gives results
comparable to existing assays.  These corroborating results indicate that significant
amounts of methanethiol are not lost to evaporation or oxidation before reacting with
DTNB, and that factors other than enzyme activity are not limiting under these
conditions.
COMPETITIVE INHIBITION OF DDAH BY L-CITRULLINE WITH THE CONTINUOUS
ASSAY
For easy visual interpretation, Lineweaver-Burk plots of DDAH inhibition by L-
citrulline were plotted and show that, at high substrate concentrations, the extrapolation
of 1/vo values from all of the substrate concentrations at each inhibitor concentration
intersect at 1/Vmax, indicating that inhibition is competitive with substrate (Figure 3.1) (54,
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55), and that L-citrulline binds at the active site, consistent with the crystallographic
observation (17).  To obtain a numerical value for Ki, the initial rate data were fit directly
to the equation for competitive inhibition, vo = ((Vmax[S])/(aKM + [S])), by fitting Vmax and
a while constraining the KM of SMTC to the value determined above.  The values
calculated for a were then plotted versus L-citrulline concentrations and the slope was
determined to give the value of Ki, (a  = 1 + [I]/ K i) (54).  Using this method, the Ki
determined for L-citrulline inhibition of PA aeruginosa DDAH is 8.4 ± 0.5 mM, a result



























Figure 3.1 Lineweaver-Burk Plot for L-Citrulline Inhibition of DDAH
 L-Citrulline is included in assay mixtures at concentrations of 0 (s), 2.13 (t), 4.26 (F),
8.52 (n), and 17.04 (l) mM.  The inset shows uninhibited DDAH-catalyzed hydrolysis
of SMTC as monitored by the DTNB assay (l ) and a fit of this data to the
Michaelis–Menten equation (solid line).
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Discussion
This novel continuous assay has other advantages over the DAMO derivatization
procedure.  For example, a crystal structure of L-citrulline bound to a mutant Pa
aeruginosa DDAH active site has been published, but the inhibition constant was not
reported.  Because the DAMO derivatization assay detects ureido groups, determining the
inhibition constant of L-citrulline is problematic due to the small amounts of L-citrulline
produced by enzyme in comparison with the concentrations used for inhibition studies.
However, the continuous assay greatly facilitates these experiments.
Although this new continuous assay has many advantages, it is not expected to
fully supplant the existing DAMO assay for several reasons.  DDAH isozymes from
different sources likely display varying sensitivities to thiol–modifying reagents (14, 35)
and this sensitivity will have to be assessed before using the DTNB-based assay.
Moreover, an artificial substrate must be used rather than the naturally occurring ADMA
and NMMA.  Also, a variety of experimental conditions are known to interfere with
DTNB-based assays and attempts to overcome these drawbacks are well described (50-
53, 56).  Despite these caveats, this new continuous assay represents a significant
advance from the known discontinuous assays of DDAH activity.  In general, DTNB-
based assays are amenable to high–throughput formats (57), so the assay reported here
could allow facile screening of both inhibitor and mutant DDAH enzyme libraries.  In
addition, unlike the DAMO derivatization assay, this continuous assay is insensitive to
compounds containing ureido groups, allowing a wider variety of inhibitors to be easily
assayed.  Because of the similarity of reactions catalyzed by other superfamily members,
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it is likely that this assay strategy could have wider applicability.  In conclusion, the use
of a commercially-available alternative substrate, SMTC, allows a quantifiable,
continuous, spectrophotometric assay of enzyme activity, which will greatly facilitate
studies of DDAH.
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Chapter 4 Active–site Directed Inactivation of DDAH
Introduction
The finding that DDAH isoforms regulate endogenous concentrations of Nw-
methyl-L-arginine (NMMA) and Nw, Nw-dimethyl-L-arginine (ADMA) (16) which serve
as nitric oxide synthase inhibitors, has made DDAH an attractive drug target.
Overproduction of nitric oxide is implicated in various disease states including septic
shock, neuronal damage during stroke, and angiogenesis (2). Thus, understanding the
normal physiological control mechanisms of nitric oxide production is of great interest as
is the ability to regulate the concentrations of endogenous methylated arginines through
the selective inhibition of DDAH activity.  The DDAH from Pseudomonas aeruginosa
(Pa) may also have a pathogenic function – one report suggests that nitric oxide may
mediate respiratory tissue damage during infection, an effect limited by ADMA (58), but
possibly encouraged by Pa DDAH.  Hence, inhibitors for both human and microbial
DDAH isoforms are desired. Inhibitors known to target the active-site specifically
include L-citrulline (17, 36), L-homocysteine (59), S-nitroso-L-homocysteine (60), zinc
(II) (21), and synthetic arginine analogs (61).  However, few specific irreversible
inhibitors have been described.
The work described here shows that 2-chloroacetamidine (Figure 4.1)(CAA), with
a substrate–like amidinium group and a chloromethylene moiety, is a time–dependent,
active–site directed inactivator of Pa DDAH.   Through kinetic analysis, site–directed






Figure 4.1 Structure of 2–chloroacetamidine (CAA)
Materials and Methods
Materials.  Synthetic DNA primers were from Sigma-Genosys (The Woodlands,
TX).  Restriction enzymes and dNTPs were from New England Biolabs (Beverly, MA).
Triplemaster polymerase was from Eppendorf (Westbury, NY).  Qiaquick purification
kits were from Qiagen (Valencia, CA).  Glu-C endoproteinase was from Roche
(Indianapolis, IN).  2-Chloroacetamidine was from Lancaster (Windham, NH).  Chelex-
100 was from BioRad (Hercules, CA).  Unless noted otherwise, all other chemicals and
buffers are from Sigma-Aldrich Chemical Co. (St. Louis, MO).  
CONSTRUCTION OF AN EXPRESSION VECTOR FOR MUTANT H162G DDAH,
PROTEIN EXPRESSION AND PURIFICATION
Two complementary mutagenic ol igonucleot ides,  (forward)
5¢–CGCCTGGAAAAGGTCCTGggcCTGAAGACCGGGCTCGCC– 3 ¢ and (reverse)
5¢–GGCGAGCCCGGTCTTCAGgccCAGGACCTTTTCCAGGCG–3¢ were designed to
introduce a mutant codon (lowercase) encoding a H162G mutation in the DDAH
sequence by overlap extension PCR (62). Briefly a 3¢ H162G megaprimer was produced
by PCR amplification from a pETpaDH template (49) using the forward mutagenic
primer and an outside T7 terminator primer (New England Biolabs) in an MJ Research
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PTC 200 thermocycler (Waltham, MA), along with dNTPs, Triplemaster polymerase and
Hi-Fidelity Buffer (Eppendorf), with a temperature program of 95º C for 5 min, followed
by 30 cycles of 95º C for 30!s, 52º C for 30!s, and 72º C for 1 min.  Construction of the 5¢
H162G megaprimer required slightly different conditions to optimize product.
Amplification was carried out by the PCR using pETpaDH as a template, the reverse
mutagenic primer described above, a specific outside primer described previously (49),
dNTPs, Triplemaster polymerase and Tuning Buffer according to protocols for GC–rich
templates (Eppendorf) by using a temperature program of 98º C for 5 min, followed by
45 cycles of 98º C for 20!s, 53º C for 10!s, and 72º C for 90!s. After Qiaquick
purification, the 5¢ and 3¢ megaprimers, the specific outside end primers described
previously, dNTPs, Triplemaster polymerase, and Tuning Buffer, were combined in a
PCR with a temperature program of 98º C for 5 min, followed by 45 cycles of 98º C for
20!s, 53º C for 10!s, and 72º C for 90!s.  The resulting H162G Pa DDAH coding
sequence was subsequently cloned between the NdeI and EcoRI restriction enzyme sites
of a pET-28a expression vector as described previously (49).  Expression and purification
of mutant H162G Pa His6-DDAH as well as C249S and wild-type Pa His6-DDAH was
completed as described previously (49).
TIME-DEPENDENT INACTIVATION OF DDAH BY 2-CHLOROACETAMIDINE (CAA)
 Purified recombinant Pa His 6-DDAH  (7.9 mM) was incubated with KCl (100
mM) and 2-chloroacetamidine (CAA, 0 – 10.5 mM) at pH 6.2 and 25º C in MES buffer
(10 mM) that was previously treated with Chelex–100 (BioRad, Hercules, CA) to remove
trace metal ions.  To test for time-dependent loss of activity, aliquots were removed from
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these incubations at time points (0 – 40 min) and diluted into an assay solution containing
an excess (1 mM) of the alternative substrate, S-methyl-L-thiocitrulline (49).  The
remaining enzyme activity was assayed by detecting methanethiol release upon substrate
hydrolysis using dithio-bis(2-nitrobenzoic acid), as described elsewhere (36).
Inactivation rates in preincubation mixtures including enzyme, CAA, and an excess of the
substrate Nw-methyl-L-arginine (10 mM) were assessed to determine whether CAA acts at
the active-site of the enzyme.  To avoid errors inherent in fitting linearized semi-log
plots, the observed pseudo first order inactivation rate constants (kobs) were determined by
direct fitting of the inactivation plots to a single exponential equation.  The resulting kobs
values were plotted against inactivator concentration and directly fit to kobs = (kinact*[I])/(KI
+ [I]) to obtain KI and k inact values (63). All fits were calculated using KaleidaGraph
software (Synergy Software, Reading, PA).  To further assay the irreversibility of
inhibition by CAA, fully inhibited DDAH was dialyzed for 24 h at 4 ºC with MES buffer
(10 mM) and KCl (100 mM) at pH 6.2 and the resulting activity was assayed as described
above.  Control reactions were run in parallel to insure that uninhibited DDAH retained
activity under these conditions.
MASS SPECTRUM ANALYSIS OF INACTIVATED DDAH AND DDAH VARIANTS
 In order to characterize any covalent adducts formed during enzyme inactivation,
30 min incubations of CAA (1 mM) with Pa His6-DDAH were carried out at 25 °C under
the same conditions used in the preincubations described above and quenched with 0.5 M
trichloroacetic acid.  Similar incubations were carried out using the C249S and H162G
mutant DDAH enzymes, and a wild type DDAH that had previously been denatured in
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MES buffer (20 mM) containing 8 M urea at a pH of 6.2. Control reactions omitting
CAA were also run in parallel.  Samples were then desalted and analyzed by ESI-MS on
a ThermoFinnigan LCQ (San Jose, CA) ion trap mass spectrometer as described
previously (49).  A control digest of untreated DDAH was also conducted and analyzed
in parallel.
IDENTIFICATION OF A COVALENTLY MODIFIED DDAH PEPTIDE
In order to determine the amino acid that is modified by CAA, the inactivated
DDAH was exchanged into 50 mM ammonium acetate buffer (pH 4) by passing through
a Sephadex G-10 spin column, digested with Glu-C endoproteinase, and the products
analyzed using MALDI-TOF and MALDI-PSD on an Applied Biosystems Voyager-DE
Pro as previously described (49) (30).  Theoretical digest masses were calculated by the
MS-Digest program in the Protein Prospector suite using two missed cleavages (31).
INCUBATION OF DDAH WITH 2-CHLOROACETAMIDE
Incubations containing DDAH (30 mM), KCl (100 mM) and 3 mM of 2-
chloroacetamide, a neutral analog of CAA were prepared at pH 6.2 and 25 oC in MES
buffer (10 mM) that was previously treated with Chelex-100 to remove trace metal ions.
To test for time-dependent loss of activity, aliquots were removed from these incubations
at time points between 0 – 15 min and assayed as described above.  Control reactions
were completed in the absence of 2-chloroacetamide.  All reactions were performed at
least in triplicate, and the data fit as described above.
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Results
CLONING, EXPRESSION, AND PURIFICATION OF MUTANT AND WILD-TYPE DDAH
ENZYMES
 DNA sequencing of the H162G variant indicated that the desired mutagenic
codon was successfully incorporated and no inadvertent mutations were introduced into
the protein coding region.  The resulting vector was used to express mutant H162G
DDAH in BL21(DE3) E.coli.  This variant, as well as the C249S and wild-type DDAH,
were purified using published procedures  to greater than 95% homogeneity as assessed
by SDS-PAGE and determined to contain less than 0.01 equiv zinc by inductively-
coupled plasma mass spectrometry (Department of Geological Sciences, The University
of Texas) (49).
TIME-DEPENDENT INACTIVATION OF DDAH BY (CAA) AND BY 2-
CHLOROACETAMIDE
  Preincubation mixtures of DDAH with CAA result in time- and concentration-
dependent enzyme inactivation, with KI and kinact values of 3.1 ± 0.8 mM and 1.2 ± 0.1
min-1, respectively (Figure 4.2).  Co-incubation with excess substrate (uninhibited kcat =
19 min-1, KM = 670 mM ) protects against inactivation, indicating that CAA acts at the
active-site of the enzyme.  Inhibition is observed after dilution of the preincubation
mixtures into a large excess of substrate and after dialysis to remove non-covalently
bound inhibitors, consistent with an irreversible mechanism.  Preincubations with the




































Figure 4.2 Time- and concentration-dependent inactivation of DDAH by CAA
(A) Exponential fits to the observed inactivation at pH 6.3, 25 oC by different
concentrations of CAA: 0 (l), 0.05 (n), 0.075 (u), 0.1 (s), 0.15(filled right triangle
pointing left), 0.25(filled right triangle pointing right), 0.5(°), 0.75(®), 3.2 (‡), 3.7 (D),
4.2 (empty triangle pointing left) 5.3(empty triangle pointing right), 8 (equilateral triangle
pointing left) and 10.5 mM (equilateral triangle pointing right). The dashed line (t)
indicates fits to inactivation by CAA (0.1 mM) in the presence of 10 mM substrate, Nw-
methyl-L-arginine.  B. Concentration dependence of the pseudo-first order kobs values for
inactivation.
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Wild Type 30503 30499 30556
Urea-denatured 30503 30497 30495
C249S 30487 30478 30479
H162G 30423 30415 30471
a The major ion peaks from deconvoluted ESI-MS spectra are reported with errors of ± 10
Da.
MASS SPECTRUM ANALYSIS OF INACTIVATED DDAH AND DDAH VARIANTS
The deconvoluted mass spectrum of a control reaction including wild-type DDAH
but no inactivator results in one major peak at 30499 ± 10 Da, matching the mass
calculated from the protein sequence, after removal of the N-terminal methionine residue
(30503 Da) (Table 4.1).  Fully inactivated DDAH results in one major peak at a different
mass of 30556 ± 10 Da, indicating the addition of a covalent adduct of 57 ± 10 Da.
Incubation mixtures with CAA and C249S DDAH, or urea-denatured DDAH do not
result in peaks that differ significantly from that predicted for unmodified protein (Table
1).  However, incubation mixtures with CAA and H162G DDAH do result in one major
peak at 30471± 10 Da, indicating a mass increase (56 ± 10 Da) over control incubations
that do not contain inactivator (30415 ± 10 Da).
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IDENTIFICATION OF A COVALENTLY MODIFIED DDAH PEPTIDE
In order to determine which amino acid of DDAH is modified during inactivation,
and to get a more precise mass of the covalent adduct, inactivated wild-type DDAH
containing the + 56 Da adduct was digested by Glu-C endoproteinase and the resulting
peptides were detected using MALDI-TOF. Sixteen different peptides were identified by
comparison with peptide molecular masses calculated from a theoretical digest.  The
observed peptides cover 66 % of the total protein sequence and include the active-site
residues Cys249, His162, Glu114, and Thr165 (Table 2).  The digestion mixture also
shows a peptide at m/z 1789.1, which does not correspond to the mass of any predicted
peptide after digestion, but is 56.1 ± 0.2 Da higher than the C-terminal peptide of DDAH
(240YRKIDGGVSCMSLRF254) after digestion by Glu-C endoproteinase.  This proposed
adduct is consistent with the 57 ± 10 Da adduct found in undigested inactivated DDAH
using ESI-MS.  Similar mass increases were not observed for any other peptides in the
digest, including the peptide containing the active site histidine residue (His162).  A
control Glu-C digest of DDAH lacking CAA did not contain any signal at m/z 1789, but
did contain the unmodified C-terminal peptide at m/z 1733.
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240-254 + Acamc 1789.2 1789.1
a Comparison of average calculated average peptide masses (MS-Digest in Protein
Prospector) for up to two missed cleavages with experimental linear MALDI-TOF
results.  Amino acid numbering is assigned to match that of Protein Data Bank entry
1H70 (17).
b.  Mass accuracy is 100 ppm, after smoothing of spectrum and internal calibration.
c. Acam stands for the acetamidine adduct shown in Figure 4.3.
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Table 4.3 Summary of major ions observed in MALDI-PSD fragmentation spectra
from m/z 1789 parent ion: YRKIDGGVSCMSLRF+Acama














a.  Acam stands for the acetamidine fragment shown in Figure 4.3
b.  Mass accuracy is 1500 ppm.  Average masses are reported.
Ions from MALDI post source decay (PSD) fragmentation spectra of the modified
C-terminal peptide at m/z 1789 were used to provide information about the site of
attachment (Table 4.3, Figure 4.3).  Ions found at m/z 84 and at m/z 129 are consistent
with the singly charged multiple immonium and related ions characteristic of lysine and
glutamine residues (64), but are both assigned here as lysine-derived ions (Table 4.3)
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because there are no glutamine residues found in the parent peptide.  The b2-NH3, b5 and
y5 daughter ions match those expected from unmodified peptide.  However, a y10* ion is
found as a fragment containing the 56.6 ± 1.7 Da adduct.  These results localize the
adduct to a residue within the 245GGVSC249 sequence.  Additional fragmentation shows a










Figure 4.3 Summary of fragmentation pattern from MALDI-PSD
A 1789 Da peptide shows b2-NH3, b5, y5, and y10* fragments.  The y10* fragment ions have
an additional mass shift of 56.6 Da due to the presence of the acetamidine adduct.
Secondary fragmentation involving neutral loss of the acetamidine modified cysteinyl
sulfur implicates Cys249 as the point of attachment.
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Discussion
2-chloroacetamidine (CAA) has a substrate–like group amidinium coupled to a
chloromethylene leaving group.  Thus we hypothesized that (CAA) might have potential
as an active–site directed inactivator of DDAH.  Indeed, pre–incubation mixtures of PA
aeruginosa DDAH with CAA resulted in a time- and concentration-dependent enzyme
inactivation, with KI and kinact values of 3.1 ± 0.8 mM and 1.2 ± 0.1 min-1, respectively
(Figure 4.2).  Inhibition is observed even after dilution of the pre–incubation mixtures
into large excesses of substrate and after dialysis to remove any non-covalently bound
inhibitors, consistent with an irreversible mechanism.  Also, co–incubation with excess
substrate protects against inactivation, indicating that CAA acts at the active–site of
DDAH.
To determine how inactivation by CAA occurs, we analyzed reaction mixtures of
CAA with wild–type DDAH, a C249S variant and a H162G variant by ESI-MS.  The
deconvoluted mass spectrum of a control reaction of wild–type DDAH without CAA
resulted in one major peak at 30499 ± 10 Da, matching the mass calculated from the
protein sequence, after removal of the N-terminal methionine residue (30503 Da).
Inactivated DDAH resulted in one major peak at a different mass of 30556 ± 10 Da,
indicating the addition of a covalent adduct of 57 ± 10 Da.  This mass increase is
consistent with the covalent addition of only one equivalent of CAA with the loss of a Cl-
































Scheme 4.1 Possible mechanisms for modification of Cys249 by (A) CAA or by (B)
2-chloroacetamide
 Incubations of the C249S variant with CAA did not result in formation of adduct,
implicating that the nucleophilicity of this residue is important to the inactivation
mechanism.  However, incubations of the H162G variant with CAA resulted in formation
of a +56 Da adduct (Table 4.1), demonstrating that His162 is not involved in formation of
adduct.
To further investigate the inactivation mechanism, we determined which residue
of DDAH is modified by CAA, by using protease digestion of control and inactivated
wild-type enzyme and subsequent MALDI-TOF MS to identify the resulting peptide
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fragments.  The linear MALDI spectrum of inactivated DDAH showed a new peak at
1789.1 ± 0.2 Da, corresponding to the mass of a C-terminal peptide containing the active-
site cysteine, (240YRKIDGGVSCMSLRF254), plus a 56.1 ± 0.2 Da adduct.  Similar mass
increases were not observed for any other peptides in the digest, including the peptide
containing the active–site His162, and were not observed in control incubations lacking
CAA.  This result gave strong evidence that the single covalent modification observed
above was attached to a residue within this peptide, most likely the active–site Cys249.
This is consistent with the observation that the C249S does not react with CAA.  The
100!ppm mass accuracy of the MALDI-MS measurements also allowed us to distinguish
between a covalent acetamidine adduct with a calculated mass difference of 56.08 Da
(Scheme 4.1 A), and a covalent acetamide adduct with a calculated mass addition of
57.06 Da (Scheme 4.1 B) in the singly charged peptide ions.  The acetamide adduct could
potentially arise through hydrolysis of the amidine either before (Scheme 4.1 B) or after
(not shown) inactivation.  Although only a small difference of 1 Da is predicted between
these two adducts, accurate MS measurements can easily distinguish the 1 Da difference
between arginine and citrulline residues arising from post-translational modifications
(65).  Here, the observed m/z increase of 56.1 ± 0.2 Da upon inactivation is consistent
with formation of a covalently attached acetamidine adduct (Scheme 4.1 A) and not
consistent with an acetamide adduct (Scheme 4.1 B).  In support of this conclusion, no
time-dependent inhibition was observed upon preincubation of DDAH with the neutral 2-
chloroacetamide under experimental conditions similar to those used for inactivation of
DDAH by CAA.  The positive charge of CAA clearly either enhances the nucleophilicity
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of Cys249, or is far more capable of binding in the active site as compared to the neutral
2-chloroacetamide.
The finding that CAA is a time dependent, active–site directed inactivator of
DDAH makes it a promising lead compound in developing a pharmacophore for
inhibiting this superfamily of enzymes (66).  We also applied CAA to a different
superfamily member peptidyl arginine deiminase IV (PAD4) and found a similar time–
and concentration– dependent inactivation, that was protected by substrate, with KI and
















Figure 4.4 Structure of N-a-benzoyl-N5-(2-fluoro-1-iminoethyl)-L-ornithineamide, and
2–chloro-1-iminoethyl-L-ornithine
Shortly after publishing our results, Luo et al., demonstrated that the
substrate–like N-a-benzoyl-N5-(2-fluoro-1-iminoethyl)-L-ornithineamide (F-amidine)
(Figure 4.4) also inactivates PAD–4, in a time and concentration dependent manner, with
a K I and kinact values of 330 mM and 1 min-1 respectively (67).   Thus in the case of
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PAD–4, the substrate like features of F-amidine yielded a kinact/KI of 3000 M-1 min-1, or
nearly 100 fold higher than the kinact/KI of 35 M-1 min-1 for CAA.  The rather high KI and
slow kinact values of DDAH inactivation by CAA, 3.1 ± 0.8 mM and 1.2 ± 0.1 min–1
respectively, will likely be similarly improved by the addition of an a–NH2/COOH
moiety and a substrate–like side chain length. An inactivator with these is proposed:
2–chloro-1-iminoethyl-L-ornithine (Figure 4.4).
These results demonstrate that the haloacetamidine moiety is effective for general
targeting of the guanidino modifying superfamily, but other structural factors will have to
be incorporated in order to achieve inactivation of specific enzymes and lower KI values.
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Chapter 5 Protonation States of Cys249 and His162 During DDAH
Catalysis
Introduction
Previously we showed that hydrolysis of an activated substrate (SMTC) by Pa
DDAH catalyzed reaction proceeds through a covalent thiouronium intermediate formed
by the active–site nucleophile, Cys249 (Chapter 2).  However, the mechanism of
nucleophilic activation has not been well addressed.  Murray-Rust et al. hypothesized that
the active site Cys249 and His162 of DDAH may form a thiolate-imidazolium ion pair as
seen in cysteine proteases (17).  However, Cys–His+ ion pair formation is unlikely
because the structure shows a distance greater than 6.5 Å between them, and the substrate
physically separates Cys249 and His162.  While exploring active site–directed inhibitors
of DDAH (Chapter 4) we noted that the positively charged 2-chloroacetamidine is a
vastly superior inactivator compared to its neutral analog 2–chloroacetamide.  We
hypothesized that the positively charged guanidino group of substrates (i.e. ADMA or
NMMA) may be integral in deprotonating Cys249 for nucleophilic attack, perhaps by
forming a substrate–Cys249 ion pair.  Herein, we determined that Cys249 exists as the
protonated thiol in the enzymes’ resting state (near physiological pH), but becomes
activated to the anionic thiolate upon binding cationic ligands.  Data obtained through pH
profiles and an H162G variant also indicates that His162 is important for both formation
of the covalent intermediate and for its decay.  Finally, a second alternative method for
continuously monitoring DDAH activity is described.
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Materials and Methods
Materials.  Unless noted otherwise, all chemicals are from Sigma-Aldrich
Chemical Co. (St. Louis, MO).  All enzymes, including wild-type Pa DDAH and the
catalytically inactive C249S and H162G Pa DDAH variants, were purified and assayed
as described previously(28, 36, 49, 66).
PH DEPENDENCE OF PA DDAH-CATALYZED HYDROLYSIS OF S-METHYL-L-
THIOCITRULLINE
Because thiol reactivity changes with pH, the continuous assay for DDAH based
on 5, 5’-dithiobis-(2-nitrobenzoic acid) (36) was not used for these experiments.  Instead,
a new assay based upon the inherent spectral differences between S-methyl-L-
thiocitrulline and the products, methanethiol and L-citrulline, was used to directly
monitor substrate hydrolysis in a continuous manner by following absorbance decreases
in the UV spectrum.  Multiple wavelengths were monitored to quantify different
concentration ranges, typically using 260 nm for high substrate concentrations (0.6 – 8
mM), 245 nm for lower concentrations (0.125 – 0.6 mM), and 235 nm for the lowest
concentrations (0.015 – 0.125 mM).    Standard curves were prepared either using S-
methyl-L-thiocitrulline or using equimolar mixtures of L-citrulline and methanethiol in
order to quantify the observed absorbance changes.  Including methanethiol in these
standard curves is particularly important at alkaline pH values because thiolates have a
higher absorbance than protonated thiols.  The accuracy of this method was verified
through comparison with parallel reactions at one selected pH (7.3), that were assayed
using both a discontinuous assay for citrulline production (28) and a continuous
spectrophotometric assay (36).  Typically, reactions of Pa DDAH (1 – 3.5 mM) with S-
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methyl-L-thiocitrulline (concentrations from 0 - 10 ¥ KM) were prepared at various pH
values (4.5 – 9.5) using the following buffers: at pH 4.5 – 5, sodium acetate (250 mM); at
pH 5.5 - 6.5, MES (250 mM); at pH 7 - 7.5, HEPES (250 mM); at  pH 8 - 8.5, Tris HCl
(250 mM); at pH 9 - 9.5, sodium borate (250 mM).  All buffers contain KCl (250 mM).
All reactions were done at least in triplicate at each pH value and the observed rates were
fit to the Michaelis-Menten equation using Kaleidagraph software (Synergy) to obtain the
steady-state rate constants.
PH DEPENDENCE OF PA DDAH-CATALYZED HYDROLYSIS OF Nw-METHYL-L-
ARGININE
A previously published discontinuous assay for L-ctirulline production (28) was
used to determine the steady-state rate constants for Pa DDAH-catalyzed hydrolysis of
Nw-methyl-L-arginine using the same conditions as described for S-methyl-L-
thiocitrulline.  All reactions were performed at least in triplicate and the observed results
were fit directly to the Michaelis-Menten equation.
FITTING THE STEADY-STATE PH-RATE DATA
Fits to the resulting kcat/KM values (Figure 1A) and kcat values (Figure 1B) for
hydrolysis of both substrates at each pH were calculated as described below.  Bell-shaped
curves were fit with a two pKa model (equation 1), rearranged as shown in equation 2, in
which y is substituted by either kcat/KM or kcat, accordingly (54, 55), and a lower limiting
term, ymin, was added to allow for a non-zero plateau at low pH values.  This ymin term
was fixed at zero when fitting data from Nw-methyl-L-arginine hydrolysis, but was left
unconstrained to obtain good fits to data from S-methyl-L-thiocitrulline hydrolysis.
Because fits to two pKa values closer than 3.5 units tend to underestimate ymax, Segel’s
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method (equations 3, 4) was used to calculate corrected pKa values for each limb of the
kcat/KM profiles (54, 55).
† 













log yobs[ ] = log ymin +
(ymax - ymin )









+]1/ 2 = K1 + 4[H
+]opt (3)
† 
[H +]opt = K1K2 (4)
Fits to the kcat values for S-methyl-L-thiocitrulline hydrolysis at each pH were calculated
using a single pKa model including a lower limiting term, kmin, to account for the non-
zero plateau at low pH as described in equation 5.
† 
log kcat[ ] = log kmin +







UV-VIS DIFFERENCE SPECTROSCOPY OF APO PROTEINS
Stock solutions of His6-tagged Pa DDAH (70 mM) and His6-tagged Pa C249S
DDAH (120 mM) were prepared as described earlier (49) and then diluted to final
concentrations of 8.3 mM and 14.1 mM, respectively, using various buffers with pH
values between 6 and 10.  The following buffers were used at the pH ranges as indicated:
at pH 5.5 – 6.5, MES (20 mM); at pH 7 – 8, HEPES (20 mM), at pH 8.5 – 10, CHES (20
mM).  All buffers contain KCl (100 mM).  The absorbance of each sample at 240 and
280 nm was measured in at least three separate experiments using a quartz micro-cuvette
and a Cary 50 UV-vis spectrophotometer (Varian, Inc., Walnut Creek, CA), after baseline
correction using the appropriate buffer as a blank.  The resulting absorbance values at
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240 nm were normalized using the 280 nm readings and then averaged for each pH value.
The (Abs240/Abs280) ratio for the C249S variant was then subtracted from the
(Abs240/Abs280) ratio determined for wild-type Pa DDAH at each pH, and then multiplied
by the calculated native extinction coefficient for Pa DDAH (e280 = 20 240 M-1 cm-1) in
order to determine the observed ∆e240 values at each pH.  The Grubbs test, calculated
with an alpha value of 0.05 using the GraphPad outlier calculator available free of charge
from http://www.graphpad.com/quickcalcs/Grubbs1.cfm, was used to remove any
outlying data points.  In order to determine the observed pKa for the absorbance changes
at 240 nm, the program KaleidaGraph (Synergy Software, Reading, PA) was used to fit
equation 6, in a procedure similar to that reported previously (68).
 
† 
e240(obs) = e240(min) +
(e240(max) -  e240(min) )
(1 +  10(pK a -pH) )
(6)
 PH DEPENDENCE OF PA DDAH INACTIVATION BY IODOACETAMIDE
Preincubation mixtures of Pa DDAH (11 mM) with varying concentrations of
iodoacetamide (0 – 2.5 mM) were prepared at various pH values (5.5 – 10) in the buffers
described above.  At pH values from 5.5 – 7.5, aliquots of the preincubation mixtures
were withdrawn at successive time points, diluted 26-fold into an assay buffer containing
an excess of the alternative substrate S-methyl-L-thiocitrulline (1 mM), potassium
phosphate (100 mM), EDTA (1 mM), 5, 5’-dithiobis-(2-nitrobenzoic acid) (200 mM), at
pH 7.3, and the remaining enzyme activity was monitored using a continuous
spectrophotometric assay as described previously (66).  Under these conditions, the
diluted iodoacetamide does not significantly interfere with our activity assay.  At pH
values greater than 8, only single time points were assayed due to the increased rate of
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inactivation.  A form of the second order rate equation (equation 7) was used to obtain
rate constants for inactivation in a procedure similar to that described elsewhere (69).
Actobs and Actinital are the observed and initial percent enzyme activities, [I] is the initial




In order to determine the observed pKa for inactivation by iodoacetamide, the resulting
kinact(obs) values, determined at each pH, were fitted with a single apparent pKa value







SUBSTRATE PROTECTION AGAINST INACTIVATION BY IODOACETAMIDE
In order to determine whether inactivation of Pa DDAH by iodoacetamide occurs by
modification at the active–site, a substrate-protection experiment was carried out.
Solutions of Pa DDAH (14 mM) in Tris buffer (250 mM) and KCl (250 mM) at pH 8.5,
were co-incubated with either iodoacetamide (1 mM) alone, or with iodoacetamide (1
mM) and Nw-methyl-L-arginine (2.5 mM).  As a control, Pa DDAH was incubated in
buffer alone.  At time points between 0 and 6 min, aliquots of the incubation mixtures
were diluted 26-fold into a buffer containing potassium phosphate (100 mM), EDTA (1
mM), 5, 5’-dithiobis-(2-nitrobenzoic acid) (180 mM), and S-methyl-L-thiocitrulline (1
mM) and assayed as described previously .  Observed rates were plotted as a percent of
the original activity against time and fit to a single exponential equation (Figure 5.5).
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MASS SPECTROMETRY OF QUENCHED REACTIONS
Typically, steady-state reactions with Pa DDAH (final concentration of 50 mM)
and substrate (5 mM) were incubated for 20 – 30 s at 25° C before addition of
trifluoroacetic acid (final concentration of 1 M), which quenches the reactions during
turnover and traps any acid-stable covalent intermediates that accumulate.  Incubations at
two different pH values were prepared in the following buffers: at pH 5.5, MES (200
mM) and at pH 8, Tris HCl (200 mM).  Both buffers contain KCl (200 mM).  Quenched
reactions were analyzed by ESI–MS as described previously (49).  Incubations with the
H162G variant (25 - 50 mM), were also completed using slightly more substrate (5 - 10
mM), and longer reaction times (3 – 10 min), and even repeated at a higher pH (9.5) in
order to maximize the chance of trapping potential intermediates during incubations with
Nw,Nw-dimethyl-L-arginine.
INHIBITION OF PA DDAH BY L-LYSINE
The steady-state rates of Pa DDAH (670 nM)-catalyzed hydrolysis of S-methyl-L-
thiocitrulline (8 – 1000 mM) were determined in varying concentrations of L-lysine (1.25
– 15 mM) in K2HPO4 (0.1 M) buffer, EDTA (1 mM), at 25º C and pH 7.3, using a
continuous assay as described earlier (36).  All reactions were done in triplicate and the
results directly fit using KaleidaGraph software (Synergy) to equation 9 for competitive
inhibition (70) where a = (1 + [I]/Ki):
† 




UV-VIS DIFFERENCE SPECTROSCOPY OF LIGAND-BOUND PROTEINS
Using a quartz micro-cuvette and a Cary!50!UV-vis spectrophotometer (Varian
Inc.), absorbance scans (230 -300 nm) were recorded for wild-type and C249S variant Pa
DDAH (4 – 5 mM) in K2HPO4 buffer (100 mM), EDTA (1 mM), pH 7.3, in the presence
of either L-lysine (10 mM) or L-citrulline (20 mM) at concentrations required to achieve
approximately 70 % saturation.  Baseline corrections were made using control solutions
in which the protein component was omitted.  All experiments were repeated at least in
triplicate and an average observed extinction coefficient was calculated at each
wavelength as described above.  The ligand-dependent changes in the observed extinction
coefficient at each wavelength were then calculated for both wild-type and C249S mutant
Pa DDAH by subtracting the results from the L-citrulline-bound proteins from those of
the L-lysine-bound proteins at each wavelength.
Results
PH DEPENDENCE OF PA DDAH-CATALYZED SUBSTRATE HYDROLYSIS
The kcat/KM values determined for S-methyl-L-thiocitrulline and Nw-methyl-L-
arginine hydrolysis (Figure 1A) both showed a bell-shaped pH dependence that was fit to
two apparent pKa values.  The fitted pKa values for S-methyl-L-thiocitrulline were 7.4 ±
0.2 for the ascending limb (slope of 0.8) and 8.8 ± 0.2 for the descending limb, with a
limiting non-zero plateau (0.2 s-1mM-1) at low pH.  The fitted pKa values for Nw-methyl-
L-arginine were 7.9 ± 0.3 for the ascending limb (slope of 1) and 9.3 ± 0.6 for the
descending limb.  Because these pairs of fitted pKa values are closer than 3 units, Segel’s
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method was used to calculate corrected pKa values of 8.0 and 8.2 for S-methyl-L-
thiocitrulline hydrolysis and 8.5 and 8.7 for Nw-methyl-L-arginine hydrolysis.
The kcat values determined for Nw-methyl-L-arginine hydrolysis (Figure 1B)
showed bell-shaped pH dependence that was fit to two apparent pKa values: 6.1 ± 0.1 for
the ascending limb (slope of 1) and 9.4 ± 0.1 for the descending limb.  The kcat values
determined for S-methyl-L-thiocitrulline hydrolysis (Figure 1B) were best fit to one
apparent pKa of 5.6 ± 0.1 for the ascending limb (slope of 0.2) and a limiting non-zero
plateau (kmin = 0.6 s
-1) at low pH values.  Pa DDAH showed linear initial rates for
substrate hydrolysis between pH values of 4.5 - 9.5, but at more acidic or alkaline pH










































Figure 5.1 pH–Rate profiles for substrate hydrolysis by wild-type Pa DDAH
A.  The kcat/KM values for S-methyl-L-thiocitrulline (l) are fit to two corrected apparent
pKa values of 8.0 and 8.2, and the kcat/KM values for Nw-methyl-L-arginine (°) are fit to
two corrected pKa values of 8.5 and 8.7 (see materials and methods for details).  B. The
kcat values for hydrolysis of S-methyl-L-thiocitrulline (l) are fit to one apparent pKa of
5.6 for the ascending limb (slope of 0.2) and a non-zero plateau (0.6 s-1) at low pH.  The
kcat values for hydrolysis of Nw-methyl-L-arginine (°) are fit to apparent pKa values of
6.1 for the ascending limb (slope of 1) and 9.4 for the descending limb.
73
UV-VIS DIFFERENCE SPECTROSCOPY OF APO PROTEINS
In order to follow the absorbance change at 240 nm due to pH-induced
deprotonation at the thiol side chain of Cys249, differences in absorbance at 240 nm
between wild-type and a C249S mutant Pa DDAH were determined (Figure 2A).  A pH-
dependent increase in absorbance at 240 nm was observed with an apparent pKa of
8.9 ± 0.2, and ∆e240(max) of   3600 ± 100 M-1cm-1.  These experimentally determined
values are consistent with typical pKa values for unperturbed non-catalytic cysteine










































Figure 5.2 Determination of the pKa of Cys249
A. UV-Vis difference spectroscopy at 240 nm between wild-type Pa DDAH and the
C249S variant showing a pH-dependent increase in absorbance with an apparent pKa of
8.9 due to thiolate formation.  B. Observed rates for inactivation of wild-type Pa DDAH
by the thiol modification reagent iodoacetamide showing a pH-dependent increase with
an apparent pKa of 8.7.
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PH DEPENDENCE OF PA DDAH INACTIVATION BY IODOACETAMIDE
Under our experimental conditions, plots of the pseudo first order inactivation rate
constants with respect to iodoacetamide concentration were linear, indicating second
order kinetics.  Consequently, the second order rate constants for inactivation at various
pH values were determined.  Addition of Nw-methyl-L-arginine (2.5 mM) to an
incubation mixture at pH 8.5 can prevent inactivation by iodoacetamide (supporting
information), indicating that inactivation is due to modification at the active–site.  The
rate of Pa DDAH inactivation by iodoacetamide increased at higher pH values (Figure
2B) and showed one apparent pKa value of 8.7 ± 0.1, matching the apparent pKa observed
for the active-site Cys249 using UV–vis difference spectroscopy (Figure 2A).  Fits of this
data to a two- pKa model did not result in a statistically significant improvement (F–test).
Using similar methods, attempts to obtain pseudo first order rate constants for
inactivation by 2-chloroacetamidine, a known affinity label, were unsuccessful due to the
rapid inactivation rates at high pH.
MASS SPECTROMETRY OF QUENCHED REACTIONS
Previous studies have shown that steady-state reactions of Pa DDAH with an
activated substrate, S-methyl-L-thiocitrulline, can be acid-quenched to trap a transient
covalent adduct of + 157 Da that accumulates during turnover and may be a catalytic
intermediate in the enzymatic mechanism (Scheme 5.1) (49).  Here, incubation mixtures
of both the wild–type and H162G proteins with the activated substrate S-methyl-L-
thiocitrulline, show the presence of the + 157 Da adduct, within error (Table 1).
However, incubation of these proteins with the naturally-occurring substrate Nw,Nw-
dimethyl-L-arginine only resulted in accumulation of a + 157 Da adduct with the wild-
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type protein.  Incubations of this natural substrate with the H162G variant only resulted
in a mass matching that of unmodified enzyme, even when incubations were repeated at a
pH value (9.5) higher than an unperturbed thiol pKa.
Figure 5.3 Deconvoluted ESI-MS spectra of trapped reactions with wild-type Pa
DDAH
Steady-state reactions of wild-type Pa DDAH and Nw-methyl-L-arginine at pH 5.5 (A)
and pH 8.0 (B), Nw, Nw-dimethyl-L-arginine at pH 8.0 (C), and S-methyl-L-thiocitrulline
at pH 5.5 (D) and 8.0 (E) were acid-trapped and then analyzed by ESI-MS to detect any
accumulation of a covalent adduct during turnover.  Marked (*) peaks are attributable to
a smaller fraction of non-enzymatically Na-gluconoylated protein modified during
expression.  The calculated mass for unmodified wild-type Pa DDAH after removal of
the N-terminal methionine is 30 503 Da.  The expected mass of the proposed covalent
intermediate is 30 660 Da.  Representative ESI-MS plots are shown and typically have an
error of ± 10 Da.
This trapping technique was also used to identify the major species that
accumulate during steady-state turnover by wild-type Pa DDAH at two different pH




















30 655 30 653
30 495
30 653 30 652
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values (Figure 5.3). At pH 5.5, trapping steady-state reactions of Nw-methyl-L-arginine
during turnover results only in protein that does not contain the + 157 Da adduct (Figure
3A).  However, when repeated at pH 8.0, trapping of these reactions results in a
significant fraction of the enzyme in which the + 157 Da covalent adduct accumulates
(Figure 3B).  At pH 5.5, trapping of reactions with S-methyl-L-thiocitrulline shows that a
mixture of unmodified enzyme and covalent adduct is present (Figure 3D), but in
reactions at a higher pH (8.0), almost all of the enzyme is trapped as the + 157 Da
covalent adduct (Figure 3E).  At pH 8.0, trapping of reactions with Nw,Nw-dimethyl-L-
arginine (Figure 3 C) also result in trapping almost all of the enzyme with the covalent
adduct.  Because the amount of covalent adduct that accumulates at high pH varies with
substrate, the kcat and KM values for Nw-methyl-L-arginine (0.59 ± 0.01 s
-1, 44 ± 4 mM),
Nw,Nw-dimethyl-L-arginine (1.27 ± 0.04 s-1, 39 ± 9 mM), and S-methyl-L-thiocitrulline
(1.30 ± 0.04 s-1, 26 ± 4 mM) were all determined at a single pH of 8.0 for comparison.
Table 5.1 Summary of major ions observed in ESI-MS spectra of acid-quenched





wild-type Pa DDAH a
Observed mass (Da) b
Incubations with
H162G Pa DDAH a
Observed mass (Da) b
Control
(without substrate)
30 495 30 415
Nw, Nw-dimethyl-L-arginine 30!652 30!416
S-methyl-L-thiocitrulline 30!653 30!573
a  The theoretical calc’d mass for wild-type Pa DDAH is 30 403, and H162G mutant Pa
DDAH is 30 423.
b  The major ion peaks from deconvoluted ESI-MS spectra are reported with errors of ±
10 Da.  All reactions were completed at pH 8 prior to the acid quench.
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INHIBITION OF PA DDAH BY L-LYSINE
L-Lysine was examined as a potential competitive inhibitor.  A double reciprocal
plot of (1/vo)5[E] versus 1/[S], determined at different L-lysine concentrations showed
linear fits that intersect at the y-axis, consistent with competitive inhibition.  Non-linear
fits to a competitive inhibition model determined a Ki for L-lysine inhibition of 4.0 ± 0.3
mM at pH 7.3.  Previously, L-citrulline was determined to be a competitive inhibitor of

















Figure 5.4 Competitive inhibition of wild-type Pa DDAH by L-lysine
For display purposes, a double-reciprocal plot is shown for inhibition of S-methyl-L-thiocitrulline
hydrolysis by 1.25 (D), 2.5 (n), 5 (l), 10 (o), and 15 (°) mM L-lysine.  Non-linear fits for
competitive inhibition indicate a Ki value of 4.0 ± 0.3 mM at pH 7.3.  See materials and methods for
experimental details.
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SUBSTRATE PROTECTS AGAINST INACTIVATION BY IODOACETAMIDE
In order to determine whether inactivation of Pa DDAH by iodoacetamide occurs by
modification at the active–site, a substrate-protection experiment was carried out. The observed rate
of P a DDAH inactivation by iodoacetamide was significantly slowed by co-incubation with
substrate, suggesting that inactivation occurs through modification at the active–site.
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Figure 5.5 Substrate protects against Pa DDAH inactivation by iodoacetamide
Control incubations of Pa DDAH (open circles) show no loss of activity.  Incubations with
iodoacetamide (closed circles) show time-dependent inactivation.  Incubations with iodoacetamide
and Nw-methyl-L-arginine (closed squares) show that substrate protects against inactivation.
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UV-VIS DIFFERENCE SPECTROSCOPY OF LIGAND-BOUND PROTEINS
Changes in absorbance near 240 nm, which are reflective of thiol deprotonation
(71), were determined by subtracting spectra of L-citrulline-bound Pa DDAH from L-
lysine-bound Pa DDAH.  The ligand concentrations used were 2.5-fold higher than their
Ki values as determined by competitive inhibition, resulting in ~ 70 % saturation.  These
difference spectra showed a relative increase in absorbance with a lmax near 235 nm and
an apparent extinction coefficient of 3 000 M-1 cm-1 (calc’d 4 300 M-1 cm-1 at full
occupancy), consistent with deprotonation of one equiv of thiol upon L-lysine binding
(Figure 4).  Parallel experiments with the C249S variant did not show a similar increase
in absorbance, indicating that Cys249 is likely the thiol that becomes deprotonated upon
ligand binding.  The structure of C249S Pa DDAH has previously been reported and
shows that this protein structure is comparable to wild-type and capable of binding L-




















Figure 5.6 UV-Vis difference spectra of Pa DDAH upon ligand binding
Spectra of L-citrulline-bound proteins are subtracted from L-lysine-bound proteins using
both wild-type (l, solid line) and C249S variant (n, dashed line) Pa DDAH, indicating




The mechanism of nucleophilic activation in the amidinotransferase superfamily
has not been well studied.  Murray–Rust et al. suggested that DDAH might have a
preformed Cys-His+ ion pair, but the structure of a Pa C249S DDAH variant shows that
product binds between these two residues (17).  Also the Nd of His162 is more than 6!Å
from the Cys249 side chain.  A Cys-His+ ion pair is therefore unlikely unless there are
significant conformational changes in the ligand–free enzyme.  Previously, we had noted
(Chapter 4) that at pH 6.3, DDAH is inactivated with the positively charged
2–chloroacetamidine but not the neutral analog 2–chloroacetamide (66). The ionization
state of Cys249 has not previously been reported, despite the importance of this
knowledge for understanding the catalytic mechanism and inhibitor design.
We first looked at the pH dependence of kcat/KM to follow ionizations in the
free–enzyme and free–substrate.  The activated substrate, SMTC, and the naturally
occurring substrate NMMA both exhibited narrow bell–shaped curves with corrected pKa
values of 8.0 and 8.2 for SMTC and 8.5 and 8.7 for NMMA (Figure 5.1).  This is
indicative of Cys249 being predominantly neutral at physiological pH values.  However,
assigning one of these pKa values to Cys249 ionization is ambiguous because of the
possibility of pH dependent changes in the rate–limiting step (72).
  To obtain more direct evidence for the pH–dependence of Cys249 ionization in
the resting enzyme we measured UV–vis difference spectra between wild–type Pa
DDAH and a C249S variant.  Thiolate anions absorb more strongly (e240 ≈ 4000 M-1
cm–1) than neutral protonated thiols (e240 ≈ 50 M-1 cm-1) (71) and UV–vis difference
spectroscopy of wild-type and C249S variant enzymes allow the measurement of
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absorbance differences due specifically to changes in ionization at Cys249, eliminating
interference from other protein residues.  This experiment resulted in an apparent pKa of
8.9 (Figure 5.2 A), which can be specifically assigned to Cys249.  We corroborated this
result by following the pH dependence of DDAH inactivation by the neutral inactivator
iodoacetamide where we determined an apparent pKa of 8.7 (Figure 5.2 B).  These pKa
values are consistent with the typical ionization values seen with non–catalytic cysteine
residues.  Thus at physiological pH values, Cys249 is predominantly in the neutral
protonated state.
We also examined the pH rate dependence of DDAH catalysis of SMTC and
NMMA hydrolysis under kcat conditions where ionizations reflect the enzyme–substrate
complex.  The pH rate curves for both substrates had similar ascending limbs (Figure 5.1
B) with an apparent pKa of 5.6 for SMTC and an apparent pKa of 6.1 for NMMA.  One
hypothesis for these observed results is that binding of the substrate assists in ionizing
Cys249.  Adjacent binding of the positively charged substrate guanidinium next to
Cys249 would be expected to cause a substantial shift in pKa.  If this interpretation is
correct, then binding of substrate would be responsible for lowering the Cys249 pKa
value by 2.8 units (from 8.9 to 6.1) reflecting a DDGKa of 3.8 kcal/mol, similar to the
typical range of DDG values (3-5 kcal/mol) reported for buried salt bridges (70).
However, instead of reflecting the ionization of particular groups, steady-state pH
rate curves can also reflect kinetic pKa values, which are instead due to changes in the
rate-limiting step of the overall reaction (70).  This seems likely to be the case for
reactions with both SMTC and NMMA.  Acid quenched steady–state reactions with
NMMA show no observable covalent adduct at pH 5.5, but a significant amount (~40%)
of adduct is observed at pH 8 (Figure 5.3!A, B respectively).  Quenched reactions with
85
SMTC show approximately 45% covalent adduct at pH 5.5 and nearly 100% adduct at
pH 8 (Figure 5.3 D, E respectively).  The accumulation of covalent adduct at high pH
values indicates that intermediate decay is at least partially rate–limiting. (It should be
noted that at the pH optimum of Pa DDAH, we are able to trap a covalent adduct that
accumulates during steady-state turnover of NMMA and asymmetrical ADMA (Figure
5.3 B, C), demonstrating that the proposed covalent intermediate can be trapped using
naturally occurring substrates and not only with an activated artificial substrate (49).)
We therefore used a direct approach to determine that binding cationic ligands can
induce Cys249 ionization.  We find that the positively charged (side–chain) L–lysine is a
competitive inhibitor of Pa DDAH (Figure 5.4), as well as the previously described
neutral (side–chain) L-citrulline (36).  This pair of ligands was used for difference
UV–vis spectroscopy with wild–type, and C249S DDAH.  Binding of a cationic ligand at
the active–site of wild–type DDAH results in an increase of absorbance near 240 nm
relative to binding a neutral ligand, with a magnitude consistent with the ionization of
one cysteine side chain (Figure 5.6).  Difference spectroscopy with the C249S variant did
not show a similar change (Figure 5.6), indicating that the observed thiolate signal is
from Cys249. These results directly show that binding a positively-charged ligand
stabilizes the anionic form of Cys249, and are consistent with a substrate-assisted
mechanism where binding of a cationic ligand lowers the pKa of the active site cysteine,
favoring deprotonation and activation of this residue as a catalytic anionic nucleophile.
The pH–rate analysis of DDAH also provides information about the role of
His162 in the catalytic mechanism.  The kcat versus pH profiles of SMTC and NMMA are
strikingly different at alkaline pH values. The kcat rates for SMTC show a pH independent
plateau at alkaline pH values while rates for NMMA show a descending limb with an
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apparent pKa of 9.4 (Figure 5.1 B).  The main difference between these two substrates is
their leaving groups, methanethiol and methylamine.  Protonation of the methanethiol
leaving group may not be strictly required for catalysis, but protonation of the
methylamine leaving group is likely essential prior to or concomitant with cleavage of the
C–N bond. This difference is reflected in the pH rate behavior, where hydrolysis of
NMMA slows at alkaline pH values, likely due to lack of protonation of the leaving
group.  The crystal structure of Pa DDAH suggests that His162 is well placed to act as an
acid in protonating the leaving group, and perhaps as a base in generating a hydroxide for
attack on the covalent intermediate (17).  Murray–Rust et al. previously reported that a
H162N DDAH variant was incapable of turnover, demonstrating that His162 is essential
to catalysis (17).  Because the alternative substrate SMTC does not likely require leaving
group protonation for intermediate formation, we hypothesized that a H162 variant may
be able to accumulate a covalent adduct with this substrate.  We incubated an H162G
DDAH variant with SMTC and found that it accumulates a covalent adduct that does not
decay (Table 5.1).  Conversely, incubations with the natural substrate ADMA and H162G
DDAH did not result in accumulation of a covalent adduct.  This result indicates that
His162 is both a general acid and general base in the DDAH catalytic mechanism.  The
finding that no covalent intermediate can be formed upon incubations with H162G and
ADMA further suggests that His162 acts as a general acid.  Because a stable covalent
reaction intermediate can form with the H162G variant shows that His162 is essential for
generating a hydroxide for intermediate hydrolysis.  Therefore the apparent pKa of 9.4 for
the descending limb of kcat versus pH profile for NMMA hydrolysis can be assigned to
His162.
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The results reported here indicate that substrate assists in the mechanism of Pa
DDAH, depressing the pKa of Cys249 sufficiently for activation of this nucleophile
(Scheme 5.1).  This mechanism has also been proposed for ubiquitin–conjugating enymes
where a catalytic cysteine is not deprotonated until substrate is bound (73).  Ligand
induced cysteine activation should be also considered in inhibitor design, because
inactivation rates of Pa DDAH by the positively charged 2–chloroacetamidine are







































Scheme 5.1 Proposed substrate–assisted activation of Cys249 and His162 as general
acid and general base in the mechanism of Pa DDAH
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Chapter 6 The Role of Glu114 in the Mechanism of DDAH
Introduction
The DDAH from Pseudomonas aeurginosa has a highly conserved active–site
containing Cys249, His162, and Glu114, although sequence alignments show that
aspartate often replaces glutamate in other related enzymes.  The structures from PA
aeurginosa and bovine DDAH suggest that the carboxyl group from Glu114 (or Asp129,
respectively) forms an ion pair with the active–site His and may be important to catalysis
(17, 18).  Murray-Rust et al. briefly investigated the PA aeurginosa DDAH active–site
Glu114 by making an E114Q variant, and reported that there was no observable activity
with the substrate ADMA (17).  In contrast, we have determined that an active–site
variant, H162G, is capable of completing a half reaction with the activated substrate
SMTC, and stably accumulates a covalent intermediate with release of the methane–thiol
leaving group (74).  We hypothesized that the use of SMTC might allow us to tease out
the role of His162 as a general acid or general base, and the effect of Glu114 as a
potential modulator of His162.  Therefore, we constructed E114Q, E114D, and E114G
substituted enzymes to more fully explore the role of Glu114.
We used the aforementioned mutant enzymes, the activated substrate SMTC,
steady–state kinetics, pH profiles, mass spectrum analysis, and metal binding studies to
elucidate the contribution of Glu114 to catalysis.
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Materials and Methods
CREATING AN EXPRESSION VECTOR FOR E114G DDAH
Two complementary oligonucleotides, (Sigma GENOSYS) (forward)
` 5 – G G C A C G G T G g g t G C C G G C G A C – ` 3 ,  a n d  ( r e v e r s e )
`5–GTCGCCGGCaccCACCGTGCC–`3 were used to introduce a mutant codon
(lowercase) coding for E114G in the Pa DDAH sequence. !The Pa DDAH gene was
amplified using an MJ Research PTC 200 thermocycler along with a plasmid containing
the wild–type DDAH coding sequence, dNTPs, 10x reaction buffer, and pfu-Turbo
polymerase (Stratagene). !The reaction conditions for the PCR used a temperature
program of 98o C for 30 s, followed by 16 cycles of 98o C for 30 s, 55o C for 1 min, and
12 min at 68o C. !The PCR-amplified products were then digested with Dpn I and
concentrated using a Qiaquick spin column (Qiagen). !The digestion product was
transformed into E.coli DH5aE cells for plasmid amplification and isolation.  The
resulting plasmid (designated pETpaE114G) was purified using a Qiaquick spin column
(Qiagen) and the coding region was sequenced to confirm that there were no undesired
mutations.! ! ! ! ! ! ! ! !
CREATING AN EXPRESSION VECTOR FOR E114D DDAH
Two complementary oligonucleotides, (Sigma GENOSYS) (forward)
` 5 – G G C A C G G T G g a c G C C G G C G A C – ` 3 ,  a n d  ( r e v e r s e )
`5–GTCGCCGGCgtcCACCGTGCC–`3 were used to introduce a mutant codon
(lowercase) coding for E114D in the Pa DDAH sequence. Amplification of the Pa
DDAH gene was performed as described above using the new mutant primers and a
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modified temperature program:  98o!C for 30 s, followed by 16 cycles of 98o!C for 30 s, a
gradient of 45–54o!C for 1 min, and 12 min at 68o!C. !The PCR-amplified products from
all annealing temperatures were combined, and digested with Dpn I, and transformed into
E.coli DH5aE cells for plasmid amplification and isolation. !The coding region in the
resulting plasmid (designated pETpaE114D) was sequenced to verify that only the
desired mutation had been incorporated.
CREATING AN EXPRESSION VECTOR FOR E114Q DDAH
The plasmid, pETpaE114Q, containing the gene for E114Q DDAH was
constructed by J. Momb, in the Fast lab.  The coding region of the resulting plasmid was
sequenced to verify that only the desired mutation had been incorporated.
OVEREXPRESSION AND PURIFICATION OF E114G, E114D, AND E114Q PA DDAH
Expression and purification of mutant E114G His6-DDAH as well as the E114D
and E114Q enzymes was completed as described previously (49), with the exception of
extending the expression time from 4!hr to 12 hr, because this was found to reduce or
eliminate the fraction of protein that undergoes post–translational N–terminal
gluconoylation (32).
STEADY–STATE KINETICS OF E114G AND E114D PA DDAH
The steady–state rate constants were determined for E114G and E114D
DDAH–catalyzed hydrolysis of SMTC using a previously published continuous assay
that measures spectral changes in DTNB upon reaction with methanethiol (36). The
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E114D mutant was assayed by addition of enzyme (920 nM) to serial dilutions of SMTC
(7!mM – 1!mM) in a Na2HPO4 buffer (100 mM), DNTB (160 mM), EDTA (1 mM), at pH
7.3. (36).  The E114G variant was assayed by addition of enzyme (1.9 mM) to serial
dilutions of SMTC (16!mM – 1!mM) in Tris buffer (250 mM), KCl (250 mM), DNTB
(185 mM), EDTA (1 mM), at pH 7.5.  The resulting data were fit directly to the
Michaelis-Menten equation using KaleidaGraph software (Synergy Software, Reading,
PA). All reactions were carried out at least in triplicate.
PH DEPENDENCE OF PA DDAH E114G & E114Q–CATALYZED HYDROLYSIS OF
SMTC
The pH rate dependence of E114G DDAH hydrolyzed SMTC was followed under
Vmax conditions with E114G DDAH (3.7!mM) and SMTC (740!mM) from pH 5 – 9.5 with
buffer conditions and a continuous DNTB based assay described previously (74).  All
reactions were completed at least in triplicate and the resulting rates were plotted against
pH and fit to equation 6.1 to assign apparent pKa values. These reactions were carried out
under saturating substrate conditions allowing kcat to be estimated by the relationship kcat =
Vmax/[E].
† 
kcat = kmin +







The pH rate dependence of E114Q DDAH–catalyzed hydrolysis of SMTC was followed
under Vmax conditions using E114Q DDAH (5.6 mM) and SMTC (740!mM) at pH 6 – 9.5
as described above.  The results were fit to equation 6.1.
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PH DEPENDENCE OF E114G DDAH CATALYZED HYDROLYSIS OF NMMA
Because different substrates can reveal different steps in the catalytic mechanism,
we also analyzed the ability of E114G DDAH to hydrolyze NMMA. A previously
published discontinuous assay for L-citrulline production (28) was used to determine a
kcat (estimated by Vmax/[E]) value for E114G DDAH catalyzed hydrolysis of NMMA as
described above for SMTC.  Typically E114G DDAH (1.2 mM), NMMA (2.4 mM), and
200!mL of each buffer were incubated 2 h at 25º C, with the exception of reactions at pH
5 which were incubated with higher concentrations (12!mM) of NMMA.  All reactions
were performed at least in triplicate and the observed rates were fit to equation 6.2 which
describe a two pKa model.
† 
kcat = kmin +
(kmax - kmin )






MASS SPECTRUM ANALYSIS OF STEADY–STATE REACTIONS OF E114G AND E114Q
PA DDAH WITH SMTC
Mixtures of E114G DDAH (45!mM) or E114Q DDAH (134!mM) and SMTC (0 or
10 mM) were reacted (1 min) at 25O C in a HEPES buffer (10 mM), KCl (100 mM), and
10 % glycerol (v/v), at pH 7.3 before being quenched by addition of trifluoroacetic acid
to a final concentration of 1.2 M.  Samples were analyzed by ESI–MS as described
previously (Chapter 2) (49).
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UV-VIS SPECTROSCOPY OF COBALT (II)-BOUND PA DDAH
Using a quartz micro-cuvette and a Cary 50 UV-vis spectrophotometer (Varian
Inc.), absorbance scans (300 - 800 nm) were recorded for wild-type (260 mM), C249S
variant (190 mM), E114G variant (50 mM), and E114Q variant (150 mM) Pa DDAH in
HEPES buffer (10 mM), KCl (100 mM), at 25º C and pH 7.3, upon addition of CoCl2 (40
– 860 mM).  Baseline corrections were made using control solutions prepared without the
protein component.  To obtain difference spectra, the absorption values of the protein
samples were subtracted, at each wavelength, from the resulting absorbance values after
addition of CoCl2.  In order to determine the apparent extinction coefficients for
absorbance changes at 340 and 600 nm, and to obtain the apparent dissociation constant
for cobalt (II) binding, the absorbance changes at each of these two wavelengths,
determined in three separate experiments, were fit to Beer’s law (equation 6.3), where   
† 
l
is the pathlength of the cuvette (1 cm), and [E•Co2+] is defined by equation 6.4 (74)
because the protein and ligand concentrations are of similar magnitude:
  
† 
Abs = e ¥ l ¥ [E •Co2+] (6.3)
† 
[E •Co2+] = ([E]+ [CoCl2]+ Kd ) - ([E]+ [CoCl2]+ Kd )





CLONING AND EXPRESSION OF GLU114 PA DDAH VARIANTS
Sequencing verified that there were no undesired mutations in any of the coding
regions for the three variants constructed.  The resulting N-terminal His6-tagged proteins
were each overexpressed in BL21 (DE3) E. coli cells, and in each case a single affinity
chromatography step resulted in purified mutant DDAH (95–98% homogeneous) as
assessed by SDS-PAGE.  Typical yields ranged between 15–45 mg/L expression culture.
STEADY–STATE KINETICS OF E114G AND E114D DDAH
The steady–state rate constants for E114G and E114D DDAH–catalyzed hydrolysis of
SMTC were determined using a previously published DNTB based assay (36). The
E114D mutant displayed virtually identical kinetics to wild–type DDAH with a kcat of
1.12 ± 0.01 s-1, and KM of 17!±!1!mM, while E114G had a reduced kcat of 0.12 ± 0.01 s-1,
and retained a similar KM of 38!±!3!mM.
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Table 6.1 Summary of kcat (s-1) values for wild–type and Glu114 mutant DDAH
(NMMA)a (SMTC)b
wild–type c 0.28 ± 0.01 1.33 ± 0.03
E114D ndd 1.12 ± 0.01
E114G 0.0024 ± 0.0004 0.15 ± 0.01
E114Q ndd 0.010 ± 0.001
a kcat was determined at pH 6, 25º C
b kcat was determined at pH 7.5, 25º C
c Values from ref. (74)
d (Not determined)
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PH DEPENDENCE OF DDAH E114G AND E114Q HYDROLYSIS OF SMTC
The kcat values determined for E114G catalysis of SMTC (Figure 6.1) fit well to
one apparent pKa of 6.0!± 0.1, a similar result to the pH rate profile of the wild–type
enzyme (Chapter 5).  The effect of this mutation results in approximately a 40–fold
reduction in kcat values at pH 5. At optimum pH (≥ 7.5) kcat values are only 8–fold less
than that of wild–type DDAH.
The kcat values obtained for E114Q hydrolysis of SMTC were plotted against pH
and fit to equation 6.1.  However the resulting curve shows only an ascending limb with
no plateau, yielding an estimated pKa of 10.  At pH 6, E114Q is approximately 1500–fold
slower than wild–type DDAH, but activity increases with pH, to within 4–fold of
wild–type values at pH 9.5.   pH values greater than 9.5 inactivate DDAH, so assays at














Figure 6.1 The pH rate dependence of E114G DDAH hydrolysis of SMTC
The kcat values are fit to one apparent pKa of 6!±!0.1 (Equation 6.1) (Log plot slope of 0.7)

















Figure 6.2 pH rate dependence of E114Q DDAH hydrolysis of SMTC
The kcat values are fit to one estimated pKa of 10! (Log plot slope of 0.8) for the ascending
limb.
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PH DEPENDENCE OF PA E114G DDAH HYDROLYSIS OF NMMA
The apparent kcat values obtained for E114G DDAH–catalyzed hydrolysis of
NMMA were plotted against pH and result in a narrow bell–shaped curve (Figure 6.3).
Fits to equation 6.2 yielded a pKa of 6.3!±!0.1 for the ascending limb and a second pKa of
8.1 ±!0.1 for the descending limb. In general, fits to two pKa values closer than 3 units
apart tend to underestimate Vmax at the pH optimum, so Segel’s method (55) (Chapter 5,
equations 5.3, 5.4) was used to calculate corrected pKa values of 6.6 and 7.8, respectively.
The kcat value observed for E114G catalyzed hydrolysis of NMMA was found to be

















Figure 6.3 pH rate dependence of E114G DDAH catalyzed hydrolysis of NMMA
The fitted kcat values yield two apparent pKa values of 6.3!±!0.1 (log plot slope of 1) for
the ascending limb and 8.1±!0.1 (log plot slope of 0.6) for the descending limb.  Because
pairs of pKa values that are closer than 3 units apart tend to underestimate Vmax, Segel’s
method (55) was used calculate the corrected pKa values of 6.6 and 7.8.
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MASS SPECTRUM ANALYSIS OF STEADY–STATE REACTIONS OF E114G AND E114Q
PA DDAH WITH SMTC
Mass spectrum analysis of control reactions (lacking substrate) of E114G DDAH
resulted in one major peak with a mass of 30!424!± 10 Da, consistent with the calculated
mass of 30!431 Da, minus the N–terminal methionine for this mutant DDAH.
Incubations of E114G with SMTC resulted in the appearance of a new major peak with a
mass of 30!582!± 10 Da, reflecting a net increase of 158!Da, consistent with the
formation of the S–alkylthiouronium reaction intermediate observed previously for
wild–type and H162G DDAH (49, 74).  Control incubations of E114Q DDAH without
substrate resulted in one major peak with a mass of 30!496!± 10 Da, consistent with the
calculated mass of 30!502 Da, minus the N–terminal methionine for this mutant DDAH.
Incubations of E114Q DDAH with SMTC resulted in a new major peak with a mass of
30!652!± 10 Da, yielding a net increase of 156!Da, consistent with the formation of the
expected covalent reaction intermediate.  Acid–quenched steady–state reactions of both
E114G and E114Q mutant DDAH with SMTC result in formation of nearly 100 %
enzyme–adduct species, demonstrating that the decay of the S–alkylthiouronium
intermediate is rate limiting during catalysis of SMTC by both of these enzymes.
UV-VIS SPECTROSCOPY OF COBALT (II)-BOUND PA DDAH
Spectral changes upon addition of CoCl2 to wild–type Pa DDAH show the
formation of a new absorbance band at 340 nm and a broad absorption band at 500 – 650
nm (Figure 6.4 A).  The features at 340 and 600 nm both appear to saturate with
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matching apparent Kd values for cobalt (II) binding of 80 ± 10 mM and 80 ± 20 mM,
respectively (Figure 6.4 B).  The apparent extinction coefficient at 340 nm is calculated
to be 860 ± 30 M-1 cm-1, similar in magnitude to the extinction coefficients reported for
one equiv of thiolate binding to cobalt (II) (75) (76).  Additionally, the broad feature
between 500 – 650 nm has a calculated extinction coefficient at 600 nm of 270 ± 10 M-1
cm-1, which has a magnitude consistent with 4- or 5-coordinate cobalt (II) complexes (75)
(77) .  Parallel experiments with a C249S mutant do not show either of the spectral
features at 340 or 600 nm (Figure 6.4 C), indicating that cobalt (II) binding likely occurs
at the active–site.  Precipitation is obvious at concentrations of CoCl2 greater than 1 mM,
precluding experiments at higher metal concentrations.  Spectral changes upon addition
of CoCl2 to E114Q DDAH show the formation of a new absorbance band at 340 nm and
a broad absorption band at 500 – 650 nm.  Observed features at 340 and 605 nm both
appear to saturate with similar apparent Kd values for cobalt (II) binding of 14 ± 8 mM
and 9 ± 5 mM, respectively (Figure 6.5) with a combined average of 12!mM.  The
apparent extinction coefficient at 340 nm is calculated to be 850 ± 60 M-1 cm-1, similar in
magnitude to the extinction coefficients reported for one equivalent of thiolate binding to
cobalt (II) (75) (76).  Additionally, the broad feature between 500 – 650 nm has a
calculated extinction coefficient at 605 nm of 380 ± 20 M-1 cm-1, which has a magnitude
consistent with 4- or 5-coordinate cobalt (II) complexes (75) (77).  Experiments with
E114G did not show any spectral features at 340 or 605 nm, indicating that this mutant
does not bind cobalt (II) at the active–site.  Protein precipitation was obvious at














































































Figure 6.4 UV–Vis spectra of cobalt (II) binding to Pa DDAH
A.  UV-Vis difference spectra are determined by subtracting the spectrum of apo Pa
DDAH from samples containing Pa DDAH (260 mM) and 40, 160, 320, 470, and 540
mM CoCl2, resulting in increases in increasing absorbance values.  B.  Increases in
absorbance at 340 (l) and 600 nm (n) upon addition of CoCl2 to Pa DDAH are fit as
described in materials and methods to yield apparent extinction coefficients of e340 (860 ±
30 M-1 cm-1) and e600 (270 ± 10 M-1 cm-1) and a Kd (80 ± 20 mM) for cobalt (II) binding.
C. UV-Vis difference spectroscopy subtracting the spectrum of apo C249S Pa DDAH
from samples containing C249S Pa DDAH (190 mM) and 220, 430, and 640 mM CoCl2.
Some protein precipitation is observed at higher CoCl2 concentrations as evidenced by
the increase in baseline.  D. Increases in absorbance at 340 (n) and 605 nm (l) upon
addition of CoCl2 to E114Q DDAH are fit as described in materials and methods to yield
apparent extinction coefficients of e340 (850 ± 60 M-1 cm-1) and e605 (380 ± 20 M-1 cm-1)
and an average Kd of 12!mM for cobalt (II) binding.
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Discussion
We sought to determine the contribution of Glu114 to catalysis by DDAH.  The
structure of a C249S mutant (pdb 1H70) complexed with citrulline shows that Glu114
makes an apparent ion pair with His162 with an interatomic distance of 2.8!Å observed
between the Ne of His162 and an oxygen of the Glu114 carboxyl.  We hypothesized that
Glu114 might be responsible for properly positioning and ionizing His162 for this
histidine’s role as general acid/base.  The E114D mutation is one methylene group
shorter and could possibly reposition His162, affecting its function.  However, this
mutation appeared to have virtually no effect on catalytic activity, displaying kcat and KM
values nearly identical to those of wild–type DDAH.  Sequence analysis of the
amidinotransferase superfamily shows that Asp often substitutes for Glu at this position.
For example, a recent structure of bovine DDAH–1 (2C6Z), has an Asp instead of Glu at
this position and gives an Asp-His+ distance of 2.6!Å, showing a structurally conserved
interaction between these two residues (18).    One interesting exception is peptidyl
arginine deiminase IV (PAD4), which has a serine at the same structural position as
Glu114.
In DDAH, a carboxylate at position 114 is quite important. E114G and E114Q are
very catalytically impaired. !Profiles of the pH dependence of kcat values for E114G
DDAH catalyzed hydrolysis of SMTC yielded a single pKa of 6 ± 0.1 with a pH
independent plateau at alkaline pH values. The kcat values at the pH optimum are only 8–
fold less than wild–type DDAH.  Mass spectral analysis of E114G incubated with SMTC
at pH 7.3 showed one major peak consistent with the mass of the covalent intermediate
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previously characterized for the wild–type enzyme (49).  This shows that at basic pH
values, the rate limiting step for E114G catalysis of SMTC is decay of the covalent
adduct (k3 Scheme 6.1), similar to that seen with wild–type DDAH (49).







Thus, because wild–type DDAH and the E114G mutant show the same rate–limiting step
the effect of an active site carboxyl on k3 can be calculated to be a DDG‡ ~!1.4 kcal/mol
(
† 
DDG* = -RT ln(kcat(wt ) /kcat(mut )) .  The pH plots of kcat values for E114G DDAH catalyzed
hydrolysis of NMMA (Figure 6.3) showed a bell shaped curve similar to that seen with
wild–type DDAH, but the curve was more narrow with an apparent pKa of 6.3!for the
ascending limb and 8.1 for the descending limb.  In comparison the wild–type DDAH pH
dependence is much broader and has apparent pKa values of 6.1 and 9.4 respectively (74).
This is consistent with Glu114 stabilizing the general acid form of His162, raising its pKa
and extends the alkaline limb from 8.1 to 9.4.  Intriguingly, superfamily member PAD–4,
which has a Ser (S406) (PDB 1WD8) at the structural position of Glu114 has a very
narrow pH rate profile, remarkably similar to that of E114G DDAH, with apparent pKa
values of 6.2 and 7.9 (78).  The lack of an active–site His+carboxyl- ion pair in PAD-4
likely explains its narrow pH rate profile.  The Ser406 residue of PAD–4 is ~3.5!Å from
the active–site His (His471), suggesting that it may orient His471 in a productive
position, thus partially fulfilling the role of Glu/Asp normally seen at this structural
position, but not effecting the ionization of His471.
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At non–optimal pH values (6.0) a different step in DDAH catalysis becomes rate
limiting.  Mass spectral analysis of wild–type DDAH incubations with NMMA show no
observable accumulation of covalent intermediate (data not shown). This indicates that
formation of the S-alkylthiouronium intermediate is rate limiting at low pH values.
Assuming that k2 (scheme 6.1) is rate limiting at pH 6.0, we can estimate the effect of
Glu114 upon His162 as a general acid.  The kinetic effect of the E114G DDAH mutation
reflects a DDG‡ on k2 of 2.8 kcal/mol towards EI formation.  This value is similar to the
typical range of DDG values (3-5 kcal/mol) reported for buried salt bridges (70), and is
consistent with the role of Glu114 stabilizing the protonated form of His162.
The E114Q mutation is also catalytically impaired but has very different
characteristics when compared to the other Glu114 mutants.  Sterically, an E114Q
mutation is very conservative, but the amide functional group is neutral so it would not be
expected to form an ion pair with H162.  ESI–MS analysis of acid quenched steady–state
reactions of E114Q and SMTC at pH 7.3 reveal that approximately 100% of the enzyme
contains the covalent adduct, demonstrating that k3 (Scheme 6.1) is rate limiting for this
mutant enzyme.  The pH rate profile for E114Q DDAH catalyzed hydrolysis of SMTC
shows a severely impaired rate at acidic pH values (≤ 5 x 10-3 s-1 at pH 6), but rapidly
increases with pH (Figure 6.2) to within 4–fold of the wild–type DDAH rate.  In
comparison, serine proteases have a conserved active site triad of Ser, His, and Asp
where His and Asp function as an ion pair, although these are oriented differently than
the catalytic triad in DDAH.  The catalytic contribution of Asp was evaluated in trypsin
by a D102N mutation, where Craik et al. noted that at neutral pH values kcat was 104
lower than wild–type but was rescued by –OH ion to within 10% of wild–type at pH 10
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(79).  It is interesting that E114Q is rescued in a similar manner.  No such rate
enhancement is seen with E114G, thus ruling out the possibility that hydroxide alone can
effectively attack the covalent intermediate.  It seems likely that the E114Q mutation
constrains His162 to a catalytically unfavored position at neutral pH values, but that high
pH values can restore His162 to a productive orientation.
To test the hypothesis that E114G and E114Q mutations constrain His162 to
different degrees, metal binding studies were conducted using cobalt (II) as a
spectroscopic probe.  Wild-type DDAH was found to bind cobalt (II) with an apparent Kd
of 80!mM (Figure 6.4 B) whereas C249S mutant DDAH was incapable of binding cobalt
(II), indicating that cobalt (II) binds at the active–site.   (An EXAFS study of
Zinc(II)–bound Pa DDAH also indicates that metals bind at the active–site, with residues
Cys249 and His162 as two of the ligands (74).)  We reasoned that if E114G and E114Q
constrain His162 to different extents, they should also have a different affinity for cobalt.
Interestingly, the E114G mutant showed no measurable affinity for cobalt (II), and was
observed to precipitate after addition of several equivalents of Co2+.  However, the
E114Q mutant was found to bind cobalt (II) with a Kd of 12!mM, approximately 7–fold
tighter than wild–type DDAH (Figure 6.5).  The spectroscopic characteristics of E114Q
bound cobalt (II) were similar to wild–type DDAH.  A ligand to metal charge transfer
(LMCT) band is observed at 340!nm with an apparent extinction coefficient of 850!M-
1cm-1 indicating cobalt bound to one thiol.  The weak features observed between 500 and
650 nm upon cobalt (II) binding are indicative of Laporte-forbidden cobalt (II) d–d
transitions, and have an extinction coefficient of 380!M–1cm-1, consistent with a 4- or 5-
coordinate cobalt (II) site.  The lack of observed metal binding for E114G suggests that
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His162 no longer occupies a favorable orientation for metal binding, consistent with its
impaired function as a general acid for protonation of the methylamine leaving group of
NMMA.  On the other hand, the E114Q mutation appears to reorient His162 to a more
favorable position for chelating metals, contributing a DDGK d of ~1.1 kcal/mol toward
binding cobalt!(II) (
† 
DDGKd = -RT ln(Kd (wt ) /Kd (mut )) ).  However, this repositioning is not
favorable for catalysis as E114Q DDAH–catalyzed hydrolysis of NMMA showed a
1500–fold reduction in kcat as compared to wild–type DDAH at pH 7.3 (Data not shown).
We propose that the function of Glu114 in the mechanism of Pa DDAH is to both
stabilize the ionized form of His162 and constrain it to a catalytically productive
orientation.  Although Glu114 is not strictly essential to catalysis, it provides nearly 3
kcal/mol towards catalyzing hydrolysis of the natural substrate NMMA and the enhanced
catalytic activity provided by this amino acid explains why it is highly conserved.
Constraining His162 to a productive orientation appears to be especially important for
protonating the methylamine leaving group of NMMA.  To a lesser extent constraining
His162 is also important to hydrolysis of the covalent intermediate.  The negative charge
of the Glu114 carboxylate is also critical to proper His162 orientation.  Constraining
His162 with the neutral E114Q mutation resulted in improved metal binding, but severely
impaired catalysis at neutral pH values.  This suggests that His162 is in a different
position when binding metals as compared to when it acts as a general acid.  In contrast,




The results of the work presented here (Chapters 2–6), provides evidence for the
roles of the active–site residues Cys249, His162, and Glu114 in the reaction mechanism
of DDAH.  During these studies we have developed two new methods for continuously
monitoring DDAH activity using the activated substrate SMTC (Chapters 3, 5).
Information about the mechanism has also led to the identification of an active–site
directed covalent inactivator motif (haloacetamidine) (Chapter 4).
We propose that the in the resting state (at physiological pH values) the
active–site Cys249 residue (Scheme 6.2) is the neutral thiol, as evidenced by UV–vis
difference spectroscopy and reactivity experiments (Chapter 5).  The positive charge of
the substrate guanidinium group depresses the pK a of Cys249, activating it for
nucleophilic attack.  This was observed directly through UV–vis difference spectroscopy
with positive– and neutral– ligands, and supported by a depressed pKa seen with kcat
versus pH profiles.  The thiolate attack on the guanidinium carbon forms a proposed
tetrahedral intermediate concomitant with protonation of the methylamine leaving group.
His162 acts as the general acid in protonating the leaving group as observed by pH
profiles and mutational studies (Chapter 5).    Glu114 plays an integral role in ionizing
and orienting the general acid form of His162, as was observed from mutational, pH
kinetic effect and spectroscopic experiments (Chapter 6). The proposed transient
tetrahedral intermediate collapses upon loss of methylamine to form a covalent























































Scheme 6.2 Proposed Reaction Mechanism of Pa DDAH
His162 acts as a general base, deprotonating H2O and generating a hydroxide ion for
attack on the covalent adduct, as deduced from mutational and ESI–MS, studies (Chapter
5).   A second proposed tetrahedral intermediate forms, which subsequently collapses to
form L–citrulline and regenerate resting enzyme.  Divalent metal ions can also bind at the
active–site, as evidenced by mutational and spectroscopic experiments (Chapter 6).
Together these experiments have outlined much of the reaction mechanism of DDAH,
114
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